Protection of low-density lipoprotein against oxidative lipoprotein associated paraoxonase

Atherosclerosis

104, 129-135

DOI: 10.1016/0021-9150(93)90183-u

Citation Report

#	Article	IF	Citations
1	Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochemical Journal, 1994, 304, 549-554.	1.7	136
2	Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7187-7191.	3.3	136
3	Serum Paraoxonase Activity, Concentration, and Phenotype Distribution in Diabetes Mellitus and Its Relationship to Serum Lipids and Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1812-1818.	1.1	350
4	HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis, 1995, 115, 243-253.	0.4	410
5	Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet, The, 1995, 346, 869-872.	6.3	337
6	Serum paraoxonase activity is decreased in uremic patients. Clinica Chimica Acta, 1996, 247, 71-80.	0.5	89
7	Relative resistance of the hamster to aortic atherosclerosis in spite of prolonged vitamin E deficiency and dietary hypercholesterolemia. Putative effect of increased HDL?. Lipids and Lipid Metabolism, 1996, 1299, 216-222.	2.6	15
8	High density lipoproteins and coronary heart disease. Atherosclerosis, 1996, 121, 1-12.	0.4	383
9	The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis, 1996, 126, 299-303.	0.4	163
10	Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. International Journal of Cardiology, 1996, 57, 69-73.	0.8	122
11	Increased selective uptake in vivo and in vitro of oxidized cholesteryl esters from high-density lipoprotein by rat liver parenchymal cells. Biochemical Journal, 1996, 319, 471-476.	1.7	43
12	Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins. Diabetologia, 1996, 39, 667-676.	2.9	35
13	Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis, 1997, 135, 193-204.	0.4	87
14	Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet, The, 1997, 349, 851-852.	6.3	156
15	Cigarette Smoke Extract Inhibits Plasma Paraoxonase Activity by Modification of the Enzyme's Free Thiols. Biochemical and Biophysical Research Communications, 1997, 236, 289-293.	1.0	164
16	Presence of paraoxonase in human interstitial fluid. FEBS Letters, 1997, 416, 377-380.	1.3	39
17	Oxidation of low-density lipoprotein and atherosclerosis in chronic renal failure. Medical Hypotheses, 1997, 49, 389-395.	0.8	3
18	Increased Immunolocalization of Paraoxonase, Clusterin, and Apolipoprotein A-I in the Human Artery Wall With the Progression of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1233-1238.	1.1	192

#	Article	IF	Citations
19	Vitamin E/Lipid Peroxide Ratio and Susceptibility of LDL to Oxidative Modification in Nonâ€“Insulin-Dependent Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1438-1446.	1.1	47
20	A ¹⁹² Arg Variant of the Human Paraoxonase (HUMPONA) Gene Polymorphism Is Associated With an Increased Risk for Coronary Artery Disease in the Japanese. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3565-3569.	1.1	151
21	Reduced Progression of Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice Following Consumption of Red Wine, or Its Polyphenols Quercetin or Catechin, Is Associated With Reduced Susceptibility of LDL to Oxidation and Aggregation. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2744-2752.	1.1	503
22	Two Alleles of the Human Paraoxonase Gene Produce Different Amounts of mRNA. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2935-2939.	1.1	159
23	Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. British Journal of Pharmacology, 1997, 122, 265-268.	2.7	171
24	High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase. Nature Medicine, 1997, 3, 744-749.	15.2	204
25	Two specific and simple methods for genotyping of the paraoxonase/arylesterase A/B polymorphism. Genetic Analysis, Techniques and Applications, 1997, 14, 9-11.	1.5	3
27	HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clinical Biochemistry, 1997, 30, 221-225.	0.8	67
28	Title is missing!. , 1998, 188, 149-159.		103
29	Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase Activities. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1617-1624.	1.1	410
30	Human Serum Paraoxonase. General Pharmacology, 1998, 31, 329-336.	0.7	287
31	A Longitudinal Analysis of Alteration in Lecithin-Cholesterol Acyltransferase and Paraoxonase Activities Following Laparoscopic Cholecystectomy Relative to Other Parameters of HDL Function and the Acute Phase Response. Scandinavian Journal of Immunology, 1998, 48, 419-424.	1.3	37
32	Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene, 1998, 213, 149-157.	1.0	163
33	Strong synergistic anti-peroxidative effects of HDL3 and ascorbic acid against copper-catalyzed LDL peroxidation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1998, 1406, 307-314.	1.8	3
34	Serum paraoxonase activity and its relationship to diabetic complications in patients with nonâ€”insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1998, 47, 598-602.	1.5	139
35	Oxidative modification of HDL3 in vitro and its effect on PLTP-mediated phospholipid transfer. Lipids and Lipid Metabolism, 1998, 1391, 181-192.	2.6	20
36	Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letters, 1998, 423, 57-60.	1.3	339
37	DNA Polymorphisms in Two Paraoxonase Genes (PON1 and PON2) Are Associated with the Risk of Coronary Heart Disease. American Journal of Human Genetics, 1998, 62, 36-44.	2.6	235

#	Article	IF	Citations
38	Oxidative stress in chronic renal failure. Free Radical Research, 1998, 29, 1-11.	1.5	83
39	Lack of Protection against Oxidative Modification of LDL by Avian HDL. Biochemical and Biophysical Research Communications, 1998, 247, 443-446.	1.0	46
40	Why plasma should not be used to study paraoxonase. Atherosclerosis, 1998, 136, 195-196.	0.4	22
41	The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis, 1998, 136, 217-223.	0.4	98
42	Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis, 1998, 137, S33-S38.	0.4	114
43	Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis, 1998, 138, 217-225.	0.4	136
44	Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis, 1998, 138, 361-366.	0.4	47
45	Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis, 1998, 139, 341-349.	0.4	249
46	The Glnâ€“Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis, 1998, 141, 259-264.	0.4	92
47	Paraoxonase as a Risk Marker for Cardiovascular Disease: Facts and Hypotheses. Clinical Chemistry and Laboratory Medicine, 1998, 36, 431-41.	1.4	53
48	Paraoxonase PON1 Polymorphism Leu-Met54 Is Associated With Carotid Atherosclerosis. Stroke, 1998, 29, 2043-2048.	1.0	104
49	Apolipoprotein A-I _{Zavalla} (Leu ₁₅₉ â†'Pro). Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1242-1247.	1.1	48
50	The Gln-Arg192 Polymorphism of Human Paraoxonase Gene Is Not Associated With Coronary Artery Disease in Italian Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1611-1616.	1.1	155
51	Comparison of the effects of fish oil and olive oil on blood lipids and aortic atherosclerosis in Watanabe heritable hyperlipidaemic rabbits. British Journal of Nutrition, 1998, 80, 565-573.	1.2	33
52	Serum Paraoxonase and Platelet-Activating Factor Acetylhydrolase in Chronic Renal Failure. Clinical Chemistry, 1998, 44, 179-181.	1.5	54
53	High Density Lipoproteins (HDL) and the Oxidative Hypothesis of Atherosclerosis. Clinical Chemistry and Laboratory Medicine, 1999, 37, 939-48.	1.4	55
54	Autoantibodies Against Oxidized Low Density Lipoprotein in Patients With Angiographically Verified Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 23-27.	1.1	185
55	Increased Atherosclerosis in ApoE and LDL Receptor Gene Knock-Out Mice as a Result of Human Cholesteryl Ester Transfer Protein Transgene Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1105-1110.	1.1	214

#	Article	IF	Citations
56	The Role of Phosphotriesterases in the Detoxication of Organophosphorus Compounds. Critical Reviews in Toxicology, 1999, 29, 21-57.	1.9	74
57	Serum Paraoxonase After Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 330-335.	1.1	262
58	Somatic Gene Transfer of Human ApoA-I Inhibits Atherosclerosis Progression in Mouse Models. Circulation, 1999, 99, 105-110.	1.6	150
59	Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification. Diabetic Medicine, 1999, 16, 415-423.	1.2	16
60	Scavenger Receptor BI Mediates the Selective Uptake of Oxidized Cholesterol Esters by Rat Liver. Journal of Biological Chemistry, 1999, 274, 8893-8899.	1.6	70
61	Role of oxidatively modified low density lipoproteins and anti-oxidants in atherothrombosis. Expert Opinion on Investigational Drugs, 1999, 8, 527-544.	1.9	8
62	Human Serum Paraoxonase/Arylesteraseâ€™s Retained HydrophobicN-Terminal Leader Sequence Associates With HDLs by Binding Phospholipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2214-2225.	1.1	290
63	Cholesteryl Ester Transfer Protein Corrects Dysfunctional High Density Lipoproteins and Reduces Aortic Atherosclerosis in Lecithin Cholesterol Acyltransferase Transgenic Mice. Journal of Biological Chemistry, 1999, 274, 36912-36920.	1.6	200
64	Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney International, 1999, 56, 289-298.	2.6	75
65	Susceptibility of serum lipids to copper-induced peroxidation correlates with the level of high density lipoprotein cholesterol. Lipids, 1999, 34, 255-259.	0.7	11
66	Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase. Chemico-Biological Interactions, 1999, 119-120, 243-249.	1.7	16
67	Low serum paraoxonase: a risk factor for atherosclerotic disease?. Chemico-Biological Interactions, 1999, 119-120, 389-397.	1.7	30
68	Paraoxonase and arylesterase activities in the serum of two hyperlipoproteinaemic patients after repeated extracorporal lipid precipitation. Chemico-Biological Interactions, 1999, 119-120, 405-411.	1.7	8
69	Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chemico-Biological Interactions, 1999, 118, 193-200.	1.7	30
70	Paraoxonase Genes and Disease. Annals of Medicine, 1999, 31, 217-224.	1.5	90
71	The role of oxidized HDL in monocyte/macrophage functions in the pathogenesis of atherosclerosis in Rhesus monkeys. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 215-225.	0.6	15
72	Serum Paraoxonase Activity Changes in Uremic and Kidney-Transplanted Patients. Nephron, 1999, 83, 126-131.	0.9	63
73	Ionizing radiation and genetic risks. Mutation Research - Reviews in Mutation Research, 1999, 436, 21-57.	2.4	38

#	Article	IF	Citations
74	Susceptibility to oxidation of copper-induced plasma lipoproteins from Japanese eel: protective effect of vitellogenin on the oxidation of very low density lipoprotein. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1999, 123, 1-7.	0.5	32
75	A Novel Lecithin-Cholesterol Acyltransferase Antioxidant Activity Prevents the Formation of Oxidized Lipids during Lipoprotein Oxidationâ€. Biochemistry, 1999, 38, 5976-5981.	1.2	87
76	HDL composition and HDL antioxidant capacity in patients on regular haemodialysis. Atherosclerosis, 1999, 143, 125-133.	0.4	33
77	Atheroprotective mechanisms of HDL. Atherosclerosis, 1999, 144, 285-301.	0.4	277
78	A simple and sensitive method in using the ratios of cholesteryl ester molecular species as indexes of oxidative stress in plasma and lipoprotein fractions. Atherosclerosis, 1999, 146, 221-235.	0.4	8
79	Remodelling of high density lipoproteins by plasma factors. Atherosclerosis, 1999, 145, 227-238.	0.4	243
80	New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol. Archives of Internal Medicine, 1999, 159, 1049.	4.3	60
81	Isolation and complete covalent structure of liver microsomal paraoxonase. Biochemical Journal, 1999, 338, 265-272.	1.7	23
82	Isolation and complete covalent structure of liver microsomal paraoxonase. Biochemical Journal, 1999, 338, 265.	1.7	16
83	Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clinical Science, 2000, 98, 355-363.	1.8	109
84	Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clinical Science, 2000, 98, 355.	1.8	59
85	Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics and Genomics, 2000, 10, 453-460.	5.7	52
86	How high-density lipoprotein protects against the effects of lipid peroxidation. Current Opinion in Lipidology, 2000, 11, 383-388.	1.2	170
87	Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrology Dialysis Transplantation, 2000, 15, 389-395.	0.4	64
88	Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. European Journal of Clinical Investigation, 2000, 30, 4-10.	1.7	83
89	Kinetic analysis of copper-induced peroxidation of HDL, autoaccelerated and tocopherol-mediated peroxidation. Free Radical Biology and Medicine, 2000, 29, 131-146.	1.3	33
90	Co-incubation of native and oxidized low-density lipoproteins: potentiation of relaxation impairment. European Journal of Pharmacology, 2000, 406, 429-437.	1.7	9
91	Human Serum Paraoxonases (PON1) Q and R Selectively Decrease Lipid Peroxides in Human Coronary and Carotid Atherosclerotic Lesions. Circulation, 2000, 101, 2510-2517.	1.6	447

#	Article	IF	Citations
92	Serum Paraoxonase and Arylesterase Activities in Hemodialysis Patients. Journal of Atherosclerosis and Thrombosis, 2000, 7, 152-158.	0.9	30
93	Intravascular Free Tissue Factor Pathway Inhibitor Is Inversely Correlated With HDL Cholesterol and Postheparin Lipoprotein Lipase but Proportional to Apolipoprotein A-II. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 251-258.	1.1	32
94	PON1 Status and Neurologic Symptom Complexes in Gulf War Veterans. Genome Research, 2000, 10, 153-155.	2.4	36
95	Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus, 2000, 9, 299-300.	0.8	34
96	Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2113-2119.	1.1	206
97	Serum lipids in young patients with ischaemic stroke: a case-control study. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 29-33.	0.9	52
98	HDLassociated PAFâ€AH reduces endothelial adhesiveness in apoE â^'/â^' mice. FASEB Journal, 2000, 14, 2032-2039.	0.2	131
99	Paraoxonase Polymorphism (Gln192Arg) as a Determinant of the Response of Human Coronary Arteries to Serotonin. Circulation, 2000, 101, 740-743.	1.6	24
100	Effect of Overexpression of Human Apo A-I in C57BL/6 and C57BL/6 Apo Eâ€"Deficient Mice on 2 Lipoprotein-Associated Enzymes, Platelet-Activating Factor Acetylhydrolase and Paraoxonase. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, E68-75.	1.1	46
101	MRI Cerebral White Matter Lesions and Paraoxonase PON1 Polymorphisms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1811-1816.	1.1	77
102	Paraoxonase Activity Is Reduced by a Pro-atherosclerotic Diet in Rabbits. Biochemical and Biophysical Research Communications, 2000, 269, 232-236.	1.0	85
103	Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism: Clinical and Experimental, 2000, 49, 1400-1405.	1.5	68
104	High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1483, 217-235.	1.2	94
105	Genetic polymorphism in paraoxonase is a risk factor for childhood focal segmental glomerulosclerosis. American Journal of Kidney Diseases, 2000, 36, 1253-1261.	2.1	23
106	Presence of CuZn superoxide dismutase in human serum lipoproteins. FEBS Letters, 2000, 467, 57-60.	1.3	18
107	Promoter Polymorphisms of Human Paraoxonase PON1 Gene and Serum Paraoxonase Activities and Concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 516-521.	1.1	279
108	Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1 ₁₉₂ or PON1 ₅₅ Genotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2441-2447.	1.1	294
109	Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis, 2000, 149, 435-442.	0.4	180

#	Article	IF	Citations
110	A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis, 2000, 150, 295-298.	0.4	150
111	PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis, 2001, 154, 641-649.	0.4	73
112	A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis, 2001, 154, 633-640.	0.4	55
113	Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis, 2001, 155, 229-235.	0.4	122
114	A multiplex PCR-based DNA assay for the detection of paraoxonase gene cluster polymorphisms. Atherosclerosis, 2001, 158, 35-40.	0.4	34
115	Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB Journal, 2001, 15, 2073-2084.	0.2	355
116	Exclusive Association of Paraoxonase 1 with High-Density Lipoprotein Particles in Apolipoprotein A-I Deficiency. Biochemical and Biophysical Research Communications, 2001, 289, 395-401.	1.0	18
117	Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. American Journal of Ophthalmology, 2001, 132, 191-195.	1.7	90
119	Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population. Metabolism: Clinical and Experimental, 2001, 50, 805-811.	1.5	24
120	Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism: Clinical and Experimental, 2001, 50, 997-1000.	1.5	66
121	Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukotrienes and Essential Fatty Acids, 2001, 65, 241-246.	1.0	42
122	A high density lipoprotein from Piaractus mesopotamicus, pacu, (Osteichthyes, Characidae), is associated with paraoxonase activity. Biochimie, 2001, 83, 945-951.	1.3	7
123	Continuous monitoring of arylesterase in human serum. Clinica Chimica Acta, 2001, 308, 69-78.	0.5	7
124	Paraoxonase Status in Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1451-1457.	1.1	409
125	Cysteine Substitutions in Apolipoprotein A-I Primary Structure Modulate Paraoxonase Activityâ€. Biochemistry, 2001, 40, 1710-1718.	1.2	85
126	Is the Oxidation of High-Density Lipoprotein Lipids Different Than the Oxidation of Low-Density Lipoprotein Lipids?â€,â€¡. Biochemistry, 2001, 40, 1719-1724.	1.2	17
127	Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochemical Journal, 2001, 354, 1-7.	1.7	129
128	High-density lipoprotein composition and paraoxonase activity in Type I diabetes. Clinical Science, 2001, 101, 659-670.	1.8	38

#	Article	IF	Citations
129	High-density lipoprotein composition and paraoxonase activity in Type I diabetes. Clinical Science, 2001, 101, 659.	1.8	20
130	Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochemical Journal, 2001, 354, 1.	1.7	87
131	Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics and Genomics, 2001, 11, 77-84.	5.7	174
132	Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins. Circulation, 2001, 104, 2376-2383.	1.6	233
133	Cerebral white matter lesions in essential hypertension. Current Hypertension Reports, 2001, 3, 429-433.	1.5	18
134	Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clinical Biochemistry, 2001, 34, 475-481.	0.8	47
135	Paraoxonase promoter polymorphism T(â€“107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. Journal of Molecular Medicine, 2001, 79, 457-463.	1.7	56
136	Interaction between the Glnâ€“Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. European Journal of Pharmacology, 2001, 432, 121-128.	1.7	62
137	Kinetics of lipid peroxidation in mixtures of HDL and LDL, mutual effects. Free Radical Biology and Medicine, 2001, 31, 1486-1497.	1.3	42
138	Paraoxonase1-192 Polymorphism Modulates the Nonfatal Myocardial Infarction Risk Associated With Decreased HDLs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 415-420.	1.1	46
139	Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins. Circulation, 2001, 104, 2498-2502.	1.6	147
140	Paraoxonase and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 473-480.	1.1	715
141	Enzymatically Active Paraoxonase-1 Is Located at the External Membrane of Producing Cells and Released by a High Affinity, Saturable, Desorption Mechanism. Journal of Biological Chemistry, 2002, 277, 4301-4308.	1.6	211
142	Proinflammatory Cytokines But Not Acute Phase Serum Amyloid A Or C-Reactive Protein, Downregulate Paraoxonase 1 (Pon1) Expression By Hepg2 Cells. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 160-164.	1.4	61
143	Effects of Inflammation on High-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1062-1063.	1.1	23
144	Vitamin C and E Intake Is Associated With Increased Paraoxonase Activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1329-1333.	1.1	174
145	Paraoxonase 192 Glnâ†'Arg Polymorphism. Stroke, 2002, 33, 1459-1464.	1.0	101
146	Human Paraoxonase1 Gene Polymorphisms and the Risk of Coronary Heart Disease: A Community-Based Study. Cardiology, 2002, 98, 116-122.	0.6	29

#	Article	IF	Citations
147	Serum Paraoxonase Activity and the Extent of Lipid Peroxidation Are not Affected by Increased Levels of Human Apolipoprotein A-I: Studies in Transgenic Mice. Clinical Chemistry and Laboratory Medicine, 2002, 40, 9-14.	1.4	7
148	The Hunt for Nutritional and Pharmacological Modulators of Paraoxonase. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1248-1250.	1.1	49
149	The paraoxonase gene family and coronary heart disease. Current Opinion in Lipidology, 2002, 13, 357-362.	1.2	92
150	Evolution of White Matter Lesions. Cerebrovascular Diseases, 2002, 13, 16-20.	0.8	116
151	Multiple Substrates for Paraoxonase-1 during Oxidation of Phosphatidylcholine by Peroxynitrite. Biochemical and Biophysical Research Communications, 2002, 290, 391-396.	1.0	84
152	Paraoxonase 1 Overexpression in Mice and Its Effect on High-Density Lipoproteins. Biochemical and Biophysical Research Communications, 2002, 290, 921-927.	1.0	89
153	Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis, 2002, 160, 425-432.	0.4	86
154	High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis, 2002, 161, 463-467.	0.4	40
155	Increased macrophage glutathione content reduces cell-mediated oxidation of LDL and atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis, 2002, 163, 17-28.	0.4	94
156	Evidence that Phospholipids Play a Key Role in Pre-Î² ApoA-I Formation and High-Density Lipoprotein Remodelingâ€. Biochemistry, 2002, 41, 12538-12545.	1.2	32
157	Genetics of Sensory Mechanotransduction. Annual Review of Genetics, 2002, 36, 411-453.	3.2	166
159	Effect of organophosphate intoxication on human serum paraoxonase. Human and Experimental Toxicology, 2002, 21, 247-252.	1.1	51
160	Genetic Factors in Susceptibility: Serum PON1 Variation Between Individuals and Species. Human and Ecological Risk Assessment (HERA), 2002, 8, 31-43.	1.7	17
161	Paraoxonase and coronary heart disease. Atherosclerosis Supplements, 2002, 3, 49-55.	1.2	133
162	Relation of lipid and lipoprotein(a) to ischaemic stroke. Journal of Clinical Neuroscience, 2002, 9, 127-132.	0.8	18
163	Increase of serum phosphatidylcholine hydroperoxide dependent on glycemic control in type 2 diabetic patients. Diabetes Research and Clinical Practice, 2002, 56, 19-25.	1.1	44
164	Serum Paraoxonase (PON1) Concentration in Patients Undergoing Hemodialysis.. Journal of Atherosclerosis and Thrombosis, 2002, 9, 133-138.	0.9	37
165	Serum Paraoxonase Activity: A New Additional Test for the Improved Evaluation of Chronic Liver Damage. Clinical Chemistry, 2002, 48, 261-268.	1.5	192

#	Article	IF	Citations
166	Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 306-311.	1.1	146
167	Dietary Modifications and Gene Polymorphisms Alter Serum Paraoxonase Activity in Healthy Women. Journal of Nutrition, 2002, 132, 3012-3017.	1.3	56
168	Contribution of HDL-apolipoproteins to the inhibition of low density lipoprotein oxidation and lipid accumulation in macrophages. Journal of Cellular Biochemistry, 2002, 86, 258-267.	1.2	10
169	Conway Memorial Lecture 2002 The dyslipidaemia of diabetes: lessons in the pathogenesis of atherosclerosis. Irish Journal of Medical Science, 2002, 171, 220-224.	0.8	0
170	Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Human Genetics, 2002, 110, 89-94.	1.8	74
171	Detection of oxidized high-density lipoprotein. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 781, 331-343.	1.2	17
172	Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. European Journal of Clinical Investigation, 2002, 32, 259-264.	1.7	111
173	Functional Genomics of the Paraoxonase (PON1) Polymorphisms: Effects on Pesticide Sensitivity, Cardiovascular Disease, and Drug Metabolism. Annual Review of Medicine, 2003, 54, 371-392.	5.0	244
174	High density lipoprotein can modulate the inhibitory effect of oxLDL on prostacyclin generation by rat aorta in vitro. Prostaglandins and Other Lipid Mediators, 2003, 72, 91-114.	1.0	2
175	Effects of red wine consumption on serum paraoxonase/arylesterase activities and on lipoprotein oxidizability in healthy-men. Journal of Nutritional Biochemistry, 2003, 14, 507-512.	1.9	27
176	Lipid metabolism and occurrence of post-percutaneous transluminal coronary angioplasty restenosis: role of cholesteryl ester transfer protein and paraoxonase/arylesterase. Journal of Thrombosis and Haemostasis, 2003, 1, 1202-1207.	1.9	10
178	High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis, 2003, 168, 195-211.	0.4	194
179	A common Ile 823 Met variant of ATP-binding cassette transporter A1 gene (ABCA1) alters high density lipoprotein cholesterol level in Japanese population. Atherosclerosis, 2003, 169, 105-112.	0.4	48
180	Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study. Circulation, 2003, 107, 2775-2779.	1.6	385
181	Antioxidant Paraoxonase 1 Activity in the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5422-5426.	1.8	163
182	Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers, 2003, 8, 1-12.	0.9	131
183	The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. Biochemical and Biophysical Research Communications, 2003, 300, 501-506.	1.0	45
184	Rapid genotyping of paraoxonase 55 and 192 mutations by melting point analysis using real time PCR technology. Clinica Chimica Acta, 2003, 332, 31-36.	0.5	15

#	Article	IF	Citations
185	Relationships between polymorphisms of the human serum paraoxonase gene and insulin sensitivity in Japanese patients with Type 2 diabetes. Diabetes Research and Clinical Practice, 2003, 60, 79-85.	1.1	12
186	Plasma platelet activating factor-acetylhydrolase (PAF-AH). Progress in Lipid Research, 2003, 42, 93-114.	5.3	120
187	Effect of homocysteinylation on human high-density lipoproteins: A correlation with paraoxonase activity. Metabolism: Clinical and Experimental, 2003, 52, 146-151.	1.5	82
188	Association between the Severity of Angiographic Coronary Artery Disease and Paraoxonase Gene Polymorphisms in the National Heart, Lung, and Blood Instituteâ€“Sponsored Womenâ€™s Ischemia Syndrome Evaluation (WISE) Study. American Journal of Human Genetics, 2003, 72, 13-22.	2.6	113
189	Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. European Journal of Internal Medicine, 2003, 14, 178-184.	1.0	54
190	Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women. Lipids in Health and Disease, 2003, 2, 4.	1.2	12
191	Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice. Circulation, 2003, 107, 1640-1646.	1.6	166
192	Distribution of Serum Paraoxon Hydrolyzing Activity in a Large Spanish Population Using a Routine Automized Method in Clinical Laboratory. Journal of Analytical Toxicology, 2003, 27, 290-293.	1.7	2
193	Oral Insulin Supplementation Attenuates Atherosclerosis Progression in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 104-110.	1.1	79
194	Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1465-1471.	1.1	118
195	The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. Journal of Lipid Research, 2003, 44, 1919-1926.	2.0	24
196	Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General Population. Clinical Chemistry, 2003, 49, 1491-1497.	1.5	143
197	Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. Cardiovascular Research, 2003, 57, 225-231.	1.8	38
198	Expression of human paraoxonase (PON1) during development. Pharmacogenetics and Genomics, 2003, 13, 357-364.	5.7	103
199	Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties. Biochemical Journal, 2003, 376, 261-268.	1.7	35
200	R/R Genotype of Human Paraoxonase(PON1) is More Protective against Lipoprotein Oxidation and Coronary Artery Disease in Japanese Subjects.. Journal of Atherosclerosis and Thrombosis, 2003, 10, 85-92.	0.9	40
201	The Ratio of Serum Paraoxonase/Arylesterase Activity Using an Improved Assay for Arylesterase Activity to Discriminate PON1R192 from PON1Q192. Journal of Atherosclerosis and Thrombosis, 2003, 10, 337-342.	0.9	37
202	Alterations of Paraoxonase and Platelet-Activating Factor Acetylhydrolase Activities in Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2004, 24, 580-589.	1.1	20

#	Article	IF	Citations
203	Identification of Gene Expression Changes Associated with the Progression of Retinal Degeneration in therd1Mouse. , 2004, 45, 2929.		88
204	Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. European Heart Journal, 2004, 25, 771-777.	1.0	31
205	Protective Effect of Paraoxonase Activity in High-Density Lipoproteins against Erythrocyte Membranes Peroxidation: A Comparison between Healthy Subjects and Type 1 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2957-2962.	1.8	102
206	Oral administration of D-003, a mixture of very long chain fatty acids prevents casein-induced endogenous hypercholesterolemia in rabbits. Canadian Journal of Physiology and Pharmacology, 2004, 82, 22-29.	0.7	13
207	Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties. Circulation Research, 2004, 95, 789-797.	2.0	118
208	High-Density Lipoproteins: A New Potential Therapeutic Target for the Prevention of Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 387-391.	1.1	127
209	High Density Lipoprotein Cholesterol and the Risk of Stroke in Elderly Men: The Honolulu Heart Program. American Journal of Epidemiology, 2004, 160, 150-157.	1.6	88
210	Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. Journal of Lipid Research, 2004, 45, 805-811.	2.0	44
211	Weight Lossâ€“Associated Induction of Peroxisome Proliferatorâ€“Activated Receptor-Î± and Peroxisome Proliferatorâ€“Activated Receptor-Î³ Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice. Circulation, 2004, 110, 3259-3269.	1.6	121
212	The Combined Effect of Paraoxonase Promoter and Coding Region Polymorphisms on the Risk of Arterial Ischemic Stroke Among Young Adults. Archives of Neurology, 2004, 61, 351.	4.9	51
213	Separation and quantitative recovery of mouse serum arylesterase and carboxylesterase activity. Journal of Lipid Research, 2004, 45, 561-566.	2.0	13
214	Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals. Clinical Chemistry, 2004, 50, 2077-2082.	1.5	32
215	Paraoxonase-1 gene Leu-Met55 and Gln-Arg192 polymorphisms are not associated with carotid artery atherosclerosis in a population-based cohort. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 511-512.	3.1	5
216	The Role of Oxidative Stress-Altered Lipoprotein Structure and Function and Microinflammation on Cardiovascular Risk in Patients with Minor Renal Dysfunction. Journal of the American Society of Nephrology: JASN, 2004, 15, 538-548.	3.0	164
217	Characterization of apoM in normal and genetically modified mice. Journal of Lipid Research, 2004, 45, 1272-1278.	2.0	67
218	Regulation of Plasma High-Density Lipoprotein Levels by the ABCA1 Transporter and the Emerging Role of High-Density Lipoprotein in the Treatment of Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1755-1760.	1.1	160
219	Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients. Diabetic Medicine, 2004, 21, 423-427.	1.2	26
220	Paraoxonase 1 192Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabetic Medicine, 2004, 21, 837-844.	1.2	23

#	Article	IF	Citations
221	Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients. Clinical Endocrinology, 2004, 61, 515-521.	1.2	59
222	Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clinical Nutrition, 2004, 23, 423-433.	2.3	550
223	Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Experimental Gerontology, 2004, 39, 629-635.	1.2	67
224	Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radical Biology and Medicine, 2004, 37, 1304-1316.	1.3	367
225	Changes in Leptin, Plasminogen Activator Factor and Oxidative Stress in Morbidly Obese Patients following Open and Laparoscopic Swedish Adjustable Gastric Banding. Obesity Surgery, 2004, 14, 659-665.	1.1	112
226	Oxidizability of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in preeclampsia. Clinical Biochemistry, 2004, 37, 990-996.	0.8	24
227	The Role of Paraoxonase 1 Activity in Cardiovascular Disease. American Journal of Cardiovascular Drugs, 2004, 4, 211-217.	1.0	123
228	FunciÃ³n antioxidante de las lipoproteÃnas de alta densidad: un nuevo paradigma en la arteriosclerosis. Revista Espanola De Cardiologia, 2004, 57, 557-569.	0.6	26
229	Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy. Endocrinology and Metabolism Clinics of North America, 2004, 33, 525-544.	1.2	13
230	The Antioxidant Function of High Density Lipoproteins: A New Paradigm in Atherosclerosis. Revista Espanola De Cardiologia (English Ed), 2004, 57, 557-569.	0.4	22
231	Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis, 2004, 173, 1-12.	0.4	233
232	Metabolic abnormalities: high-density lipoproteins. Endocrinology and Metabolism Clinics of North America, 2004, 33, 393-403.	1.2	21
233	Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene, 2004, 327, 153-160.	1.0	50
234	Effects of eggplant (Solanum melongena) on the atherogenesis and oxidative stress in LDL receptor knock out mice (LDLRâ¯/â¯). Food and Chemical Toxicology, 2004, 42, 1259-1267.	1.8	16
235	Acetylcholine esterase protects LDL against oxidation. Biochemical and Biophysical Research Communications, 2004, 322, 974-978.	1.0	34
236	Serum paraoxonase activity and lipid parameters in the early postpartum period of dairy cows. Research in Veterinary Science, 2004, 76, 57-61.	0.9	59
237	Paraoxonase 192 polymorphism and its relationship to serum lipids in Turkish renal transplant recipients. Transplantation Proceedings, 2004, 36, 1385-1386.	0.3	7
238	Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism: Clinical and Experimental, 2004, 53, 297-302.	1.5	102

#	Article	IF	Citations
239	A comparison of HDL and LDL cholesterol for prevalent coronary calcification. International Journal of Cardiology, 2004, 95, 55-60.	0.8	35
240	Focus on high-density lipoproteins in reducing cardiovascular risk. American Heart Journal, 2004, 148, S14-S18.	1.2	38
241	Role of Oxidative Modifications in Atherosclerosis. Physiological Reviews, 2004, 84, 1381-1478.	13.1	2,186
242	Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid. Atherosclerosis, 2004, 176, 57-62.	0.4	13
243	Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. Atherosclerosis, 2004, 177, 167-174.	0.4	20
244	Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis, 2004, 177, 203-210.	0.4	63
245	HDL: a recipe for longevity. Atherosclerosis Supplements, 2004, 5, 25-31.	1.2	39
246	Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Current Opinion in Lipidology, 2004, 15, 399-404.	1.2	88
247	Polymorphisms of the Paraoxonase Gene and Risk of Preterm Delivery. Epidemiology, 2004, 15, 466-470.	1.2	53
248	Atherosclerosis: cell biology and lipoproteins. Current Opinion in Lipidology, 2004, 15, 93-95.	1.2	0
249	Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial communityThe Bogalusa Heart Study. Atherosclerosis, 2004, 177, 167-174.	0.4	34
250	Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clinical Science, 2004, 107, 435-447.	1.8	226
251	Enzyme-Linked Immunosorbent Assay for Bovine Apolipoprotein A-IV. Journal of Veterinary Medical Science, 2004, 66, 1199-1204.	0.3	4
252	Both HDL3 and HDL2 Exert a Powerful Anti-Oxidative and Protective Effect against Acceleration of Oxidative Modification of LDL by Ascorbic Acid. Journal of Nutritional Science and Vitaminology, 2005, 51, 75-79.	0.2	3
253	The paraoxonase-2-310 polymorphism is associated with the presence of microvascular complications in diabetes mellitus. Journal of Internal Medicine, 2005, 258, 363-368.	2.7	35
254	Cloning, high level expression of human paraoxonase-3 in Sf9 cells and pharmacological characterization of its product. Biochemical Pharmacology, 2005, 70, 1019-1025.	2.0	10
255	Protective Effect of Policosanol on Atherosclerotic Plaque on Aortas in Monkeys. Archives of Medical Research, 2005, 36, 441-447.	1.5	15
256	The paraoxonase gene family and atherosclerosis. Free Radical Biology and Medicine, 2005, 38, 153-163.	1.3	255

#	Article	IF	Citations
257	Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radical Biology and Medicine, 2005, 38, 164-174.	1.3	64
258	Emerging role of high-density lipoprotein in the prevention of cardiovascular disease. Drug Discovery Today, 2005, 10, 1095-1101.	3.2	24
259	Oxidative stress and serum paraoxonase activity in experimental hypothyroidism: effect of vitamin E supplementation. Cell Biochemistry and Function, 2005, 23, 1-8.	1.4	95
260	Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease. Clinical and Experimental Medicine, 2005, 5, 20-30.	1.9	20
261	Paraoxonase 1 status in the Thai population. Journal of Human Genetics, 2005, 50, 293-300.	1.1	38
262	Obesity and lipids. Current Cardiology Reports, 2005, 7, 465-470.	1.3	42
263	Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics, 2005, 5, 2619-2630.	1.3	78
264	Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World Journal of Gastroenterology, 2005, 11, 7351.	1.4	74
265	Association of genes of lipid metabolism with measures of subclinical cardiovascular disease in the Diabetes Heart Study. Journal of Medical Genetics, 2005, 42, 720-724.	1.5	19
266	Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. Journal of Lipid Research, 2005, 46, 389-403.	2.0	202
267	The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. Journal of Lipid Research, 2005, 46, 1888-1895.	2.0	47
268	Facilitated replacement of Kupffer cells expressing a paraoxonase-1 transgene is essential for ameliorating atherosclerosis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11029-11034.	3.3	38
269	Dietary Antioxidants and Paraoxonases Against LDL Oxidation and Atherosclerosis Development. Handbook of Experimental Pharmacology, 2005, , 263-300.	0.9	97
270	Evaluation of the Paraoxonases as Candidate Genes for Stroke. Stroke, 2005, 36, 2346-2350.	1.0	72
271	Iron, Lipids, and Risk of Cancer in the Framingham Offspring Cohort. American Journal of Epidemiology, 2005, 161, 1115-1122.	1.6	57
272	Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis, 2005, 180, 55-61.	0.4	60
273	High-density lipoprotein cholesterol in the cardiovascular equation: Does the â€œgoodâ€•still count?. Atherosclerosis, 2005, 180, 217-223.	0.4	21
274	Effects of inflammation on plasma composition and endothelial structure and function. , 2005, 15, 94-98.		15

#	Article	IF	Citations
275	Paraoxonase 1-192Q Allele is a Risk Factor for Idiopathic Chronic Pancreatitis. Molecular Diagnosis and Therapy, 2005, 9, 9-15.	1.3	5
276	Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. Journal of Lipid Research, 2005, 46, 445-451.	2.0	80
277	Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism: Clinical and Experimental, 2005, 54, 142-150.	1.5	44
278	HDL-C and the diabetic patient: Target for therapeutic intervention?. Diabetes Research and Clinical Practice, 2005, 68, S36-S42.	1.1	20
279	Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 72, 203-209.	1.0	45
280	Effects of green tea on serum paraoxonase/arylesterase activities in streptozotocin-induced diabetic rats. Nutrition Research, 2005, 25, 1061-1074.	1.3	26
281	Sleep-Disordered Breathing and Cerebrovascular Disease: A Mechanistic Approach. Neurologic Clinics, 2005, 23, 1059-1075.	0.8	97
283	Role of oxidative stress in diabetic nephropathy. Advances in Chronic Kidney Disease, 2005, 12, 146-154.	0.6	93
284	Roles of Paraoxonase and Oxidative Stress in Adolescents with Uraemic, Essential or Obesity-Induced Hypertension. Kidney and Blood Pressure Research, 2006, 29, 144-151.	0.9	22
285	Paraoxonase-2 Deficiency Aggravates Atherosclerosis in Mice Despite Lower Apolipoprotein-B-containing Lipoproteins. Journal of Biological Chemistry, 2006, 281, 29491-29500.	1.6	149
286	High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis, 2006, 186, 396-401.	0.4	49
287	Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis, 2006, 187, 74.e1-74.e10.	0.4	125
288	Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 47, 2429-2435.	1.2	77
289	Cloning, purification, and refolding of human paraoxonase-3 expressed in Escherichia coli and its characterization. Protein Expression and Purification, 2006, 46, 92-99.	0.6	24
290	Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1103-1108.	2.5	49
291	Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population. Chinese Medical Journal, 2006, 119, 1204-1209.	0.9	23
292	Antiatherogenic role of high-density lipoproteins: insights from genetically engineered-mice. Frontiers in Bioscience - Landmark, 2006, 11, 1328.	3.0	18
293	The PON1192RR genotype is associated with a higher prevalence of arterial hypertension. Journal of Hypertension, 2006, 24, 1293-1298.	0.3	13

#	Article	IF	Citations
294	From Oxidative Stress to Cardiovascular Risk in Obstructive Sleep Apnoea. Vom oxidativen Stress zum kardiovaskularen Risiko bei obstruktiver Schlafapnoe. Somnologie, 2006, 10, 113-119.	0.9	1
295	ROSIGLITAZONE MODULATES FASTING AND POST-PRANDIAL PARAOXONASE 1 ACTIVITY IN TYPE 2 DIABETIC PATIENTS. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 1134-1137.	0.9	33
296	The association of the PON1 Q192R polymorphism with complications and outcomes of pregnancy: findings from the British Women's Heart and Health cohort study. Paediatric and Perinatal Epidemiology, 2006, 20, 244-250.	0.8	28
297	Effects of caloric restriction and gender on rat serum paraoxonase 1 activity. Journal of Nutritional Biochemistry, 2006, 17, 197-203.	1.9	27
298	Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clinical Biochemistry, 2006, 39, 191-195.	0.8	46
299	Plasma Paraoxonase Activities, Lipoprotein Oxidation, and Trace Element Interaction in Asthmatic Patients. Biological Trace Element Research, 2006, 111, 41-52.	1.9	24
300	Paraoxonase 1 gene polymorphisms influence clinical features of open-angle glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 984-990.	1.0	13
301	Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia, 2006, 49, 1380-1386.	2.9	96
302	Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. European Journal of Pharmacology, 2006, 544, 104-110.	1.7	40
303	The metabolic syndrome. Journal of Diabetes and Its Complications, 2006, 20, 121-132.	1.2	79
304	Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas. Cell Biochemistry and Function, 2006, 24, 455-460.	1.4	30
305	Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population. Neurological Research, 2006, 28, 549-554.	0.6	33
306	Bile Acids Decrease Hepatic Paraoxonase 1 Expression and Plasma High-Density Lipoprotein Levels Via FXR-Mediated Signaling of FGFR4. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 301-306.	1.1	63
307	Association between Inflammation and Malnutrition as Risk Factors of Cardiovascular Disease. Blood Purification, 2006, 24, 51-55.	0.9	46
308	Are the health benefits of fish oils limited by products of oxidation?. Nutrition Research Reviews, 2006, 19, 53-62.	2.1	75
309	High Density Lipoprotein Associated Paraoxonase1 Activity in Relation to Oxidative Stress in CAD Patients. Current Cardiology Reviews, 2006, 2, 125-129.	0.6	3
310	Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1545-1550.	1.1	157
311	A long and winding road: defining the biological role and clinical importance of paraoxonases. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1052-9.	1.4	78

#	Article	IF	Citations
312	Defective Metabolism of Oxidized Phospholipid by HDL From People With Type 2 Diabetes. Diabetes, 2006, 55, 3099-3103.	0.3	55
313	The age-related paraoxonase 1 response is altered by long-term caloric restriction in male and female rats. Journal of Lipid Research, 2006, 47, 2042-2048.	2.0	10
314	TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. Journal of Lipid Research, 2006, 47, 1014-1024.	2.0	27
315	The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. Journal of Lipid Research, 2006, 47, 2492-2502.	2.0	118
316	Increased Oxidative Stress in Scavenger Receptor BI Knockout Mice With Dysfunctional HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2413-2419.	1.1	56
317	Polymorphisms and Vascular Cognitive Impairment After Ischemic Stroke. Journal of Geriatric Psychiatry and Neurology, 2007, 20, 93-99.	1.2	21
318	Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease. Human Reproduction, 2007, 23, 100-104.	0.4	67
319	The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. Journal of Lipid Research, 2007, 48, 1637-1646.	2.0	77
320	Ingestion of moderately thermally oxidized polyunsaturated fat decreases serum resistance to oxidation in men with coronary artery disease. Nutrition Research, 2007, 27, 265-272.	1.3	2
321	Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis, 2007, 194, 175-181.	0.4	62
323	Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment. Journal of Psychopharmacology, 2007, 21, 857-863.	2.0	42
324	Intrinsic enzymes of high-density lipoprotein. Journal of Clinical Lipidology, 2007, 1, 20-30.	0.6	4
327	The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clinical Biochemistry, 2007, 40, 1-5.	0.8	56
328	HIGH-DOSE TAURINE SUPPLEMENTATION INCREASES SERUM PARAOXONASE AND ARYLESTERASE ACTIVITIES IN EXPERIMENTAL HYPOTHYROIDISM. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 833-837.	0.9	14
329	Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chemico-Biological Interactions, 2007, 167, 63-70.	1.7	49
330	Paraoxonases are associated with intestinal inflammatory diseases and intracellularly localized to the endoplasmic reticulum. Free Radical Biology and Medicine, 2007, 43, 730-739.	1.3	61
331	PON1, A New Biomarker of Cardiovascular Disease, Is Low in Patients with Systemic Vasculitis. Seminars in Arthritis and Rheumatism, 2007, 37, 149-155.	1.6	14
332	HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Current Cardiology Reports, 2007, 9, 486-492.	1.3	40

#	Article	IF	Citations
333	The role of paraoxonase (PON) enzyme in the extent and severity of the coronary artery disease in type-2 diabetic patients. Heart and Vessels, 2007, 22, 158-164.	0.5	18
334	Paraoxonase (PON)1 192R Allele Carriage is Associated with Reduced Risk of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2007, 52, 2707-2715.	1.1	22
335	Time-dependent modulation of rat serum paraoxonase 1 activity by fasting. Pflugers Archiv European Journal of Physiology, 2007, 453, 831-837.	1.3	7
336	Paraoxonase-1 activity as a marker of atherosclerosis is not associated with low bone mineral density in healthy postmenopausal women. Archives of Gynecology and Obstetrics, 2007, 275, 353-359.	0.8	10
337	PON1 activity and total oxidant status in patients with active pulmonary tuberculosis. Clinical Biochemistry, 2008, 41, 140-144.	0.8	35
338	Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clinical Biochemistry, 2008, 41, 1-9.	0.8	52
339	Maternal chronic hepatitis B virus is implicated with low neonatal paraoxonase/arylesterase activities. Clinical Biochemistry, 2008, 41, 282-287.	0.8	17
340	Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein Eâ€deficient mice with preâ€existing atherosclerosis. British Journal of Pharmacology, 2008, 153, 508-516.	2.7	49
341	Serum PON1 arylesterase activity in relation to hyperhomocysteinaemia and oxidative stress in young adult central retinal venous occlusion patients. Eye, 2008, 22, 969-974.	1.1	16
342	ASSOCIATION BETWEEN PPARGC1A GENE POLYMORPHISMS AND CORONARY ARTERY DISEASE IN A CHINESE POPULATION. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 1172-1177.	0.9	22
343	ParaoxonaseÂ1 phenotype distribution and activity differs in subjects with newly diagnosed TypeÂ2 diabetes (the CODAM Study). Diabetic Medicine, 2008, 25, 186-193.	1.2	28
344	Glycation of paraoxonaseâ€1 inhibits its activity and impairs the ability of highâ€density lipoprotein to metabolize membrane lipid hydroperoxides. Diabetic Medicine, 2008, 25, 1049-1055.	1.2	104
345	The human paraoxonaseâ€1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. British Journal of Clinical Pharmacology, 2008, 66, 366-374.	1.1	51
346	Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Radical Biology and Medicine, 2008, 45, 743-748.	1.3	42
347	High glucose induces transactivation of the human paraoxonase 1 gene in hepatocytes. Metabolism: Clinical and Experimental, 2008, 57, 1725-1732.	1.5	22
348	Paraoxonaseâ€1 Activity in Subfertile Men and Relationship to Sperm Parameters. Journal of Andrology, 2009, 30, 183-189.	2.0	34
350	Glucose Inactivates Paraoxonase 1 (PON1) and Displaces it from High Density Lipoprotein (HDL) to a Free PON1 Form. , 2008, , 35-49.		4
351	Paraoxonase-1 and Cardiovascular Disease. , 2008, , 51-60.		0

#	Article	IF	Citations
352	Association Between Paraoxonase-1 and Paraoxonase-2 Polymorphisms and the Risk of Acute Myocardial Infarction. Revista Espanola De Cardiologia (English Ed), 2008, 61, 269-275.	0.4	5
353	Effect of spermine on lipid profile and HDL functionality in the streptozotocin-induced diabetic rat model. Life Sciences, 2008, 82, 301-307.	2.0	37
354	Influence of oxidative stress and metabolic adaptation on PON1 activity and MDA level in transition dairy cows. Animal Reproduction Science, 2008, 108, 98-106.	0.5	78
355	Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis, 2008, 196, 122-128.	0.4	34
356	Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: The PRIME study. Atherosclerosis, 2008, 197, 556-563.	0.4	32
357	Platelet activating factor-acetylhydrolase (PAF-AH) activity and HDL levels, but not PAF-AH gene polymorphisms, are associated with successful aging in Sicilian octogenarians. Aging Clinical and Experimental Research, 2008, 20, 171-177.	1.4	7
358	Atherosclerosis in primary antiphospholipid syndrome. Expert Review of Clinical Immunology, 2008, 4, 53-60.	1.3	3
359	Paraoxonase 1: Genetics and Activities During Aging. Rejuvenation Research, 2008, 11, 113-127.	0.9	38
360	Dynamic variation in allele-specific gene expression of Paraoxonase-1 in murine and human tissues. Human Molecular Genetics, 2008, 17, 3263-3270.	1.4	15
361	Effect of Statins on Serum Apolipoprotein J and Paraoxonase-1 Levels in Patients With Ischemic Heart Disease Undergoing Coronary Angiography. Angiology, 2008, 59, 137-144.	0.8	9
362	High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain. Clinical Chemistry and Laboratory Medicine, 2008, 46, 809-13.	1.4	6
363	Association between Human Paraoxonase 1 Activity and Intima-Media Thickness in Subjects under 55 Years of Age with Carotid Artery Disease. Cerebrovascular Diseases, 2008, 25, 122-128.	0.8	23
364	Association of Serum Lipid Profile and Arteriovenous Fistula Thrombosis in Maintenance Hemodialysis Patients. Blood Purification, 2008, 26, 322-332.	0.9	15
365	The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opinion on Pharmacotherapy, 2008, 9, 3151-3158.	0.9	33
366	Paraoxonase-1 activity in patients with hyperemesis gravidarum. Redox Report, 2008, 13, 134-138.	1.4	16
367	Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology, 2008, 48, 26-31.	0.9	79
368	Lipid peroxidation in stroke patients. Clinical Chemistry and Laboratory Medicine, 2008, 46, 113-7.	1.4	34
369	The Influence of PON1 192 Polymorphism on Endothelial Function in Diabetic Subjects with or without Hypertension. Hypertension Research, 2008, 31, 507-513.	1.5	13

#	Article	IF	Citations
370	The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose. Coronary Artery Disease, 2008, 19, 565-573.	0.3	15
371	Excess coronary artery disease risk in South Asian immigrants: Can dysfunctional high-density lipoprotein explain increased risk?. Vascular Health and Risk Management, 2008, Volume 4, 953-961.	1.0	43
372	Procoagulant activities of plasma factor VIIc and factor Xc are positively and independently associated with concentrations of the high-density lipoprotein apolipoprotein, apo A-II. Thrombosis and Haemostasis, 2008, 100, 391-396.	1.8	4
373	High-density lipoproteins: the guardian angel of the cell membrane. Mediterranean Journal of Nutrition and Metabolism, 2009, 2, 93-96.	0.2	0
374	Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World Journal of Gastroenterology, 2009, 15, 1929.	1.4	45
375	Validation of reported physical activity for cholesterol control using two different physical activity instruments. Vascular Health and Risk Management, 2009, 5, 649.	1.0	10
376	Islet Endothelial Activation and Oxidative Stress Gene Expression Is Reduced by IL-1Ra Treatment in the Type 2 Diabetic GK Rat. PLoS ONE, 2009, 4, e6963.	1.1	54
377	The paraoxonases: role in human diseases and methodological difficulties in measurement. Critical Reviews in Clinical Laboratory Sciences, 2009, 46, 83-106.	2.7	215
378	Is Plasma Homocysteine Level Associated With Metabolic Syndrome Components in Adolescents?. Metabolic Syndrome and Related Disorders, 2009, 7, 357-362.	0.5	16
379	Relations of Lipid Concentrations to Heart Failure Incidence. Circulation, 2009, 120, 2345-2351.	1.6	120
380	Evaluation of Polymorphisms in Paraoxonase 2 <i>(PON2)</i> Gene and Their Association with Cardiovascular-Renal Disease Risk in Mexican Americans. Kidney and Blood Pressure Research, 2009, 32, 200-204.	0.9	10
381	Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. Clinical Lipidology, 2009, 4, 331-341.	0.4	10
382	Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity. Mini-Reviews in Medicinal Chemistry, 2009, 9, 911-920.	1.1	32
383	Gene expression profiling of experimental asthma reveals a possible role of paraoxonase-1 in the disease. International Immunology, 2009, 21, 967-975.	1.8	35
384	Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters. Phytomedicine, 2009, 16, 652-658.	2.3	82
385	Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochemistry and Function, 2009, 27, 176-180.	1.4	69
386	Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetologica, 2009, 46, 239-242.	1.2	43
387	The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clinical Biochemistry, 2009, 42, 91-98.	0.8	59

#	Article	IF	Citations
388	Association of oxidative stress and paraoxonase status with PROCAM risk score. Clinical Biochemistry, 2009, 42, 617-623.	0.8	14
389	Coronary Artery Diseases in South Asian Immigrants: An Update on High Density Lipoprotein Role in Disease Prevention. Journal of Immigrant and Minority Health, 2009, 11, 415-421.	0.8	7
390	Alterations in the High Density Lipoprotein Phenotype and HDLâ€Associated Enzymes in Subjects with Metabolic Syndrome. Lipids, 2009, 44, 9-16.	0.7	69
391	High-density lipoprotein/apolipoprotein A-I infusion therapy. Current Atherosclerosis Reports, 2009, 11, 58-63.	2.0	43
392	High-density lipoproteins: the guardian angel of the cell membrane. Mediterranean Journal of Nutrition and Metabolism, 2009, 2, 93-96.	0.2	0
393	Effect of efavirenz on highâ€density lipoprotein antioxidant properties in HIVâ€infected patients. British Journal of Clinical Pharmacology, 2009, 68, 891-897.	1.1	10
394	Polymorphism of the paraoxonase (PON-1) gene in the Slavonic part of the Kharkiv population. Cytology and Genetics, 2009, 43, 348-351.	0.2	0
395	Paraoxonase2 C311S polymorphism and low levels of HDL contribute to a higher mortality risk after acute myocardial infarction in elderly patients. Molecular Genetics and Metabolism, 2009, 98, 314-318.	0.5	19
397	Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacological Reports, 2009, 61, 892-898.	1.5	52
398	Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radical Research, 2009, 43, 772-782.	1.5	29
399	Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis, 2009, 202, 439-445.	0.4	39
400	Variation in paraoxonase-1 activity and atherosclerosis. Current Opinion in Lipidology, 2009, 20, 265-274.	1.2	101
401	Acute Effects of Statin Therapy on Coronary Atherosclerosis Following an Acute Coronary Syndrome. Yearbook of Endocrinology, 2010, 2010, 43-47.	0.0	0
402	Paraoxonase Variants Relate to 10-Year Risk in Coronary Artery Disease: Impact of a High-Density Lipoproteinâ€"Bound Antioxidant in Secondary Prevention. Yearbook of Endocrinology, 2010, 2010, 41-43.	0.0	0
403	Paraoxonase Activity in Athletic Adolescents. Pediatric Exercise Science, 2010, 22, 93-104.	0.5	20
404	Comparative modeling of PON2 and analysis of its substrate binding interactions using computational methods. Journal of Ocular Biology, Diseases, and Informatics, 2010, 3, 64-72.	0.2	8
405	Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis. European Journal of Epidemiology, 2010, 25, 449-458.	2.5	39
406	Role of protein kinase C in pitavastatin-induced human paraoxonase I expression in Huh7 cells. Metabolism: Clinical and Experimental, 2010, 59, 1287-1293.	1.5	16

#	Article	IF	Citations
407	The molecular basis of human retinal and vitreoretinal diseases. Progress in Retinal and Eye Research, 2010, 29, 335-375.	7.3	485
408	Human tissue distribution of paraoxonases 1 and 2 mRNA. IUBMB Life, 2010, 62, 480-482.	1.5	53
409	Matrix metalloproteinaseâ€9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects. Journal of Clinical Laboratory Analysis, 2010, 24, 305-310.	0.9	18
410	HDL 2 Particles are associated with hyperglycaemia, lower PON1 activity and oxidative stress in type 2 diabetes mellitus patients. Clinical Biochemistry, 2010, 43, 1230-1235.	0.8	22
411	Lower paraoxonase 1 activity in Tunisian bipolar I patients. Annals of General Psychiatry, 2010, 9, 36.	1.2	14
412	Molecular Mechanisms of HDL-Cholesterol Elevation by Statins and Its Effects on HDL Functions. Journal of Atherosclerosis and Thrombosis, 2010, 17, 436-451.	0.9	83
413	Functional Change in the HDL Particle by Oxidative Modification and its Contribution to Atherogenesis. , 2010, , 215-241.		0
414	The Effect of Grape Seed Extracts on Serum Paraoxonase Activities in Streptozotocin-Induced Diabetic Rats. Journal of Medicinal Food, 2010, 13, 725-728.	0.8	28
415	High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease. , 2010, , .		6
416	Relationship Between High Density Lipoprotein Antioxidant Activity and Carotid Arterial Intima-Media Thickness in Patients with Essential Hypertension. Clinical and Experimental Hypertension, 2010, 32, 13-20.	0.5	16
417	Paraoxonase: Its antiatherogenic role in chronic renal failure. Indian Journal of Nephrology, 2010, 20, 9.	0.2	16
418	Genetic Association Between Single Nucleotide Polymorphisms in the Paraoxonase 1 (PON1) Gene and Small-for-Gestational-Age Birth in Related and Unrelated Subjects. American Journal of Epidemiology, 2010, 171, 999-1006.	1.6	13
419	Human PON Promoters: From Similarity to Prediction of Polymorphic Positions within Transcription Factor Elements. Mini-Reviews in Medicinal Chemistry, 2010, 10, 938-945.	1.1	1
420	Ghrelin, Nitrite and Paraoxonase/Arylesterase Concentrations in Cement Plant Workers. Journal of Medical Biochemistry, 2010, 29, 78-83.	0.7	16
421	The Change of Ghrelin Levels in Intestinal Parasitic Infections. Journal of Medical Biochemistry, 2010, 29, 34-38.	0.7	3
422	The Role of Oxidative Stress and Antioxidant Defenses in Buerger Disease and Atherosclerotic Peripheral Arterial Occlusive Disease. Annals of Vascular Surgery, 2010, 24, 455-460.	0.4	19
423	RÃ1e du stress oxydatif et des dÃ©fenses anti-oxydantes dans la maladie de Buerger et les lÃ©sions artÃ©rielles occlusives athÃ©romateuses pÃ©riphÃ©riques. Annales De Chirurgie Vasculaire, 2010, 24, 497-503.	0.0	0
424	HDLâ€paraoxonase and Membrane Lipid Peroxidation: A Comparison Between Healthy and Obese Subjects. Obesity, 2010, 18, 1079-1084.	1.5	69

#	Article	IF	Citations
425	Anti-atherogenic property of ferulic acid in apolipoprotein E-deficient mice fed Western diet: Comparison with clofibrate. Food and Chemical Toxicology, 2010, 48, 2298-2303.	1.8	60
426	Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids in Health and Disease, 2010, 9, 46.	1.2	32
427	The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opinion on Pharmacotherapy, 2011, 12, 2605-2611.	0.9	28
428	Semi-Targeted Plasma Proteomics Discovery Workflow Utilizing Two-Stage Protein Depletion and Off-Line LCâ˜'MALDI MS/MS. Journal of Proteome Research, 2011, 10, 34-45.	1.8	26
429	Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: A meta-analysis based on 88 caseâ€"control studies. Atherosclerosis, 2011, 214, 377-385.	0.4	80
430	Effects of Intronic and Exonic Polymorphisms of Paraoxonase 1 (PON1) Gene on Serum PON1 Activity in a Korean Population. Journal of Korean Medical Science, 2011, 26, 720.	1.1	19
431	Metabolic Complications of Chronic Kidney Failure and Hemodialysis. , 2011, , .		1
432	Paraoxonase and arylesterase activities in stent restenosis in bare metal stent. Coronary Artery Disease, 2011, 22, 289-293.	0.3	3
433	Susceptibility of LDL and its subfractions to glycation. Current Opinion in Lipidology, 2011, 22, 254-261.	1.2	75
434	HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radical Biology and Medicine, 2011, 50, 102-109.	1.3	92
435	Q192R polymorphism of PON-1 gene in type 2 diabetes patients. Cytology and Genetics, 2011, 45, 38-40.	0.2	5
436	Influence of dietary supplementation withBacillus-fermented adlay on lipid metabolism, antioxidant status and intestinal microflora in hamsters. Journal of the Science of Food and Agriculture, 2011, 91, 2271-2276.	1.7	21
437	Serum paraoxonaseâ€1 activities and oxidative status in patients with plaqueâ€type psoriasis with/without metabolic syndrome. Journal of Clinical Laboratory Analysis, 2011, 25, 289-295.	0.9	22
438	Lovastatin enhances paraoxonase enzyme activity and quells low-density lipoprotein susceptibility to oxidation in type 2 diabetic nephropathy. Clinical Biochemistry, 2011, 44, 165-170.	0.8	9
439	Serum paraoxonase and arylesterase activities in patients with lacunar infarction: A case control study. Clinical Biochemistry, 2011, 44, 288-292.	0.8	6
440	The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1246-1257.	1.8	105
441	Decreased paraoxonase 1 activity and increased oxidative stress in low leadâ˜'exposed workers. Human and Experimental Toxicology, 2011, 30, 1196-1203.	1.1	19
442	Paraoxonase-1 and oxidative status in common Mediterranean Î²-thalassaemia mutations trait, and their relations to atherosclerosis. Journal of Clinical Pathology, 2011, 64, 437-442.	1.0	15

#	Article	IF	Citations
443	Curcumin induces paraoxonase 1 in cultured hepatocytes in vitro but not in mouse liver in vivo. British Journal of Nutrition, 2011, 105, 167-170.	1.2	25
444	Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Review of Cardiovascular Therapy, 2011, 9, 355-366.	0.6	16
445	Associations of Cholesterol and Glucose with Cardiovascular Dysfunction in Black Africans: The SABPA Study. Clinical and Experimental Hypertension, 2011, 33, 159-166.	0.5	4
446	Serum Levels of Lipids, Lipoproteins and Paraoxonase Activity in Pre-Eclampsia. Journal of International Medical Research, 2011, 39, 1427-1431.	0.4	28
447	Antioxidant and anti-inflammatory role of paraoxonase 1: Implication in arteriosclerosis diseases. North American Journal of Medical Sciences, 2012, 4, 523.	1.7	166
448	Paraoxonase 1 (PON1) C/T-108 Association With Longitudinal Mean Arterial Blood Pressure. American Journal of Hypertension, 2012, 25, 1188-1194.	1.0	6
449	Paraoxonase-1 55 LL Genotype Is Associated with No ST-Elevation Myocardial Infarction and with High Levels of Myoglobin. Journal of Lipids, 2012, 2012, 1-5.	1.9	6
450	Low Levels of Serum Paraoxonase Activities are Characteristic of Metabolic Syndrome and May Influence the Metabolic-Syndrome-Related Risk of Coronary Artery Disease. Experimental Diabetes Research, 2012, 2012, 1-9.	3.8	26
451	Hormonal and Chemical Regulation of Paraoxonases in Mice. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 688-695.	1.3	22
452	Low High-Density Lipoprotein Cholesterol Is Not Responsible for Decreased Paraoxonase Activity in Chronic Renal Failure. Kidney and Blood Pressure Research, 2012, 35, 265-272.	0.9	3
453	Additional Common Polymorphisms in thePONGene Cluster Predict PON1 Activity but Not Vascular Disease. Journal of Lipids, 2012, 2012, 1-11.	1.9	32
454	Lipid Peroxidation and Paraoxonase-1 Activity in Celiac Disease. Journal of Lipids, 2012, 2012, 1-7.	1.9	16
455	Increased Levels of Human Carotid Lesion Linoleic Acid Hydroperoxide in Symptomatic and Asymptomatic Patients Is Inversely Correlated with Serum HDL and Paraoxonase 1 Activity. Journal of Lipids, 2012, 2012, 1-9.	1.9	15
456	PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways. PPAR Research, 2012, 2012, 1-10.	1.1	43
457	Dietary cholesterol increases paraoxonase 1 enzyme activity. Journal of Lipid Research, 2012, 53, 2450-2458.	2.0	37
458	SERUM PARAOXONASE PHENOTYPE DISTRIBUTION IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION AND ITS RELATIONSHIP TO HOMOCYSTEINE AND OXIDIZED LOW-DENSITY LIPOPROTEIN. Retina, 2012, 32, 658-666.	1.0	19
459	The growing importance of PON1 in cardiovascular health. Journal of Cardiovascular Medicine, 2012, 13, 443-453.	0.6	32
460	Paraoxonase 1 and homocysteine metabolism. Amino Acids, 2012, 43, 1405-1417.	1.2	89

#	Article	IF	Citations
461	Quantitative Assessment of the Influence of Paraoxonase 1 Activity and Coronary Heart Disease Risk. DNA and Cell Biology, 2012, 31, 975-982.	0.9	50
462	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocrine Practice, 2012, 18, 1-78.	1.1	386
463	Paraoxonase Enzyme Activity Is Enhanced by Zinc Supplementation in Hemodialysis Patients. Renal Failure, 2012, 34, 1123-1128.	0.8	30
464	Association between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studies. Molecular Genetics and Metabolism, 2012, 105, 141-148.	0.5	58
465	Low serum PON1 activity: An independent risk factor for coronary artery disease in Northâ€“West Indian type 2 diabetics. Gene, 2012, 498, 13-19.	1.0	25
466	Genistein as a potential inducer of the antiâ€atherogenic enzyme paraoxonaseâ€1: studies in cultured hepatocytes in vitro and in rat liver in vivo. Journal of Cellular and Molecular Medicine, 2012, 16, 2331-2341.	1.6	19
467	Î²-carotene reverses the IL-1Î²-mediated reduction in paraoxonase-1 expression via induction of the CaMKKII pathway in human endothelial cells. Microvascular Research, 2012, 84, 297-305.	1.1	21
468	Effects of rosemary on lipid profile in diabetic rats. African Journal of Plant Science, 2012, 6, .	0.4	5
469	Genetic Determinants of Dietary Antioxidant Status. Progress in Molecular Biology and Translational Science, 2012, 108, 179-200.	0.9	20
470	Paraoxonase 1 (PON1) Activity, Polymorphisms and Coronary Artery Disease. , 0, , .		1
471	Electrocardiogram (ECG) Abnormality Among Residents in Arseniasis-Endemic and Non-Endemic Areas of Southwestern Taiwan â€“ A Study of Gene-Gene and Gene-Environment Interactions. , 2012, , .		0
472	Paraoxonase-1 activity and the levels of lipids and lipid peroxidation markers in arterial versus venous blood samples in coronary angiography patients. Postepy W Kardiologii Interwencyjnej, 2012, 3, 199-204.	0.1	3
473	HDL-Associated Paraoxonase 1 Gene Polymorphisms as a Genetic Markers for Wide Spread Diseases. , 2012, , .		1
474	Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. British Journal of Dermatology, 2012, 166, 204-207.	1.4	70
475	Trichinella spiralis: Infection changes serum paraoxonase-1 levels, lipid profile, and oxidative status in rats. Experimental Parasitology, 2012, 131, 190-194.	0.5	12
476	Paraoxonase 1 gene (Gln192â€“Arg) polymorphism and the risk of coronary artery disease in type 2 diabetes mellitus. Egyptian Heart Journal, 2012, 64, 55-62.	0.4	5
477	The effect of poloxamer 407 on the functional properties of HDL in mice. Journal of Pharmacy and Pharmacology, 2012, 64, 677-687.	1.2	6
478	The Q192R polymorphism of the paraoxonase 1 gene is a risk factor for coronary artery disease in Saudi subjects. Molecular and Cellular Biochemistry, 2013, 380, 121-128.	1.4	38

#	Article	IF	Citations
479	Association between PON1 genetic polymorphisms and miscarriage in Mexican women exposed to pesticides. Science of the Total Environment, 2013, 449, 302-308.	3.9	15
480	Effect of virgin coconut oil enriched diet on the antioxidant status and paraoxonase 1 activity in ameliorating the oxidative stress in rats â€“ a comparative study. Food and Function, 2013, 4, 1402.	2.1	52
481	Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids in Health and Disease, 2013, 12, 183.	1.2	15
482	Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure. Environment International, 2013, 56, 42-47.	4.8	50
483	Association of Paraoxonase1 Gene Q192R Polymorphism and Apolipoprotein B in Asian Indian Women with Coronary Artery Disease Risk. Genetic Testing and Molecular Biomarkers, 2013, 17, 140-146.	0.3	4
484	Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: A practical zymogram method to assess HDL function. Clinica Chimica Acta, 2013, 415, 162-168.	0.5	32
485	Paraoxonases. Advances in Clinical Chemistry, 2013, 59, 65-100.	1.8	29
486	Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease. Atherosclerosis, 2013, 231, 308-314.	0.4	36
487	High-Density Lipoprotein Subfractions - What the Clinicians Need to Know. Cardiology, 2013, 124, 116-125.	0.6	509
488	Investigation ofin vivoeffect of florfenicol on metabolic-antioxidant enzymesâ€™ activities on Morkaraman normal and lactating sheep. Journal of Taibah University for Science, 2013, 7, 189-194.	1.1	1
489	Impaired antioxidant action of high density lipoprotein in patients with type 1 diabetes with normoalbuminuria and microalbuminuria. Diabetes Research and Clinical Practice, 2013, 99, 321-326.	1.1	13
490	Targeting paraoxonase-1 in atherosclerosis. Expert Opinion on Therapeutic Targets, 2013, 17, 829-837.	1.5	47
491	Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics, 2013, 14, 1495-1515.	0.6	35
492	Diesel Exhaust Induces Systemic Lipid Peroxidation and Development of Dysfunctional Pro-Oxidant and Pro-Inflammatory High-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1153-1161.	1.1	127
493	Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian Journal of Endocrinology and Metabolism, 2013, 17, 402.	0.2	54
494	Paraoxonase 1 activities and genetic variation in childhood obesity. British Journal of Nutrition, 2013, 110, 1639-1647.	1.2	28
495	Prooxidative Effects of Ambient Pollutant Chemicals Are Inhibited by HDL. Journal of Biochemical and Molecular Toxicology, 2013, 27, 172-183.	1.4	22
496	Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. Journal of Lipid Research, 2013, 54, 552-560.	2.0	17

#	Article	IF	Citations
497	Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. Thrombosis and Haemostasis, 2013, 109, 854-868.	1.8	49
498	Total Serum Oxidant/Antioxidant Status and Arylesterase Activity in Recurrent Aphthous Stomatitis. Annals of Dermatology, 2013, 25, 273.	0.3	23
499	Serum paraoxonase activity and lipid hydroperoxide levels in adult football players after three days football tournament. African Health Sciences, 2013, 13, 565-70.	0.3	8
500	Association of paraoxonase polymorphisms with carotid artery atherosclerosis in essential hypertension patients. Genetics and Molecular Research, 2013, 12, 5174-5185.	0.3	4
501	Paraoxonase1 activity, its Q192R polymorphism and diabetic retinopathy in type 2 diabetes mellitus.. International Journal of Biomedical and Advance Research, 2014, 5, 35.	0.1	2
502	Purification of Paraoxonase Enzyme From the Sera of Patients with Behcetâ€™s Disease and Analyzing the Effects of the Drugs Containing Imuran (Azathioprine), Prednisolone (Methylprednisolone) and Colchium (Colchicine). Drug Metabolism Letters, 2014, 8, 67-75.	0.5	3
503	Aerobic Training Modulates the Effects of Exercise-Induced Oxidative Stress on PON1 Activity: A Preliminary Study. Scientific World Journal, The, 2014, 2014, 1-6.	0.8	19
504	Paraoxonases and Chemokine (Câ€“C Motif) Ligand-2 in Noncommunicable Diseases. Advances in Clinical Chemistry, 2014, 63, 247-308.	1.8	32
505	Monitoring of the lactonase activity of paraoxonase-1 enzyme in HIV-1-infection. Journal of the International AIDS Society, 2014, 17, 19682.	1.2	3
506	Current Aspects of Paraoxonase-1 Research. , 2014, , 273-291.		2
507	Effect of rosemary (Rosmarinus officinalis) on lipid profiles and blood glucose in human diabetic patients (type-2). African Journal of Biochemistry Research, 2014, 8, 147-150.	0.2	13
509	HDLâ€3 is a Superior Predictor of Carotid Artery Disease in a Caseâ€Control Cohort of 1725 Participants. Journal of the American Heart Association, 2014, 3, e000902.	1.6	35
510	Paraoxonase1, its Q192R polymorphism and HDL-cholesterol in relation to intensive cardiac care unit stay in ischemic heart disease. Indian Journal of Human Genetics, 2014, 20, 51.	0.7	5
511	Human Paraoxonase-1 Activity Is Related to the Number of CD4+ T-Cells and Is Restored by Antiretroviral Therapy in HIV-1-Infected Individuals. Disease Markers, 2014, 2014, 1-7.	0.6	10
512	Effects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants. Nutrition and Metabolism, 2014, 11, 44.	1.3	16
513	Oxidized High-Density Lipoprotein. , 2014, , 247-272.		1
514	Proteomic Diversity in HDL. , 2014, , 293-322.		2
515	Harbingers of Neonatal Birth Weight: The PON1 Arylesterase and Lactonase Activities. Turkish Journal of Biochemistry, 2014, 39, 25-29.	0.3	3

#	Article	IF	Citations
516	Leptin and paraoxonase activity in cord blood from obese mothers. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 1353-1356.	0.7	27
517	Correlation of Paraoxonase1 Activities with Birth Weight. Indian Journal of Pediatrics, 2014, 81, 760-761.	0.3	2
518	Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in JapaneseÂpatients with dyslipidemia. Atherosclerosis, 2014, 237, 577-583.	0.4	80
519	Genotype and phenotype frequencies of paraoxonase 1 in fertile and infertile men. Systems Biology in Reproductive Medicine, 2014, 60, 361-366.	1.0	15
520	The Effect ofIn VitroDieldrin Exposure on the Rat Paraoxonase 1 (Pon1) Promoter. Journal of Biochemical and Molecular Toxicology, 2014, 28, 224-231.	1.4	4
521	Quantification of the arylesterase activity of paraoxonase-1 in human blood. Analytical Methods, 2014, 6, 289-294.	1.3	13
522	Paraoxonase (PON1) activity in patients with subclinical thoracic aortic atherosclerosis. International Journal of Cardiovascular Imaging, 2014, 30, 889-895.	0.7	8
523	Pharmacology of conjugated equine estrogens: Efficacy, safety and mechanism of action. Journal of Steroid Biochemistry and Molecular Biology, 2014, 142, 16-29.	1.2	87
524	Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis, 2014, 237, 208-219.	0.4	519
525	Serum paraoxonase-1 activity in children: the eff ects of obesity and insulin resistance. Acta Cardiologica, 2014, 69, 679-685.	0.3	11
526	How HDL protects LDL against atherogenic modification. Current Opinion in Lipidology, 2015, 26, 247-256.	1.2	34
527	Paraoxonase and Arylesterase Activities in Dipper and Non-Dipper Prehypertensive Subjects. Medicine (United States), 2015, 94, e786.	0.4	3
528	Effects of Anaerobic Training on Paraoxonase-1 Enzyme (PON1) Activities of High Density Lipoprotein Subgroups and Its Relationship with PON1-Q192R Phenotype. Journal of Atherosclerosis and Thrombosis, 2015, 22, 313-326.	0.9	7
529	Antioxidant properties of HDL. Frontiers in Pharmacology, 2015, 6, 222.	1.6	112
530	The Impact of Modern Antiretroviral Therapy on Lipid Metabolism of HIV-1 Infected Patients. , 2015, , .		1
531	Immunohistochemical Analysis of Paraoxonases and Chemokines in Arteries of Patients with Peripheral Artery Disease. International Journal of Molecular Sciences, 2015, 16, 11323-11338.	1.8	23
532	Association of paraoxonase-1 activity and major depressive disorder in patients with metabolic syndrome. International Journal of Diabetes in Developing Countries, 2015, 35, 258-263.	0.3	0
533	Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene, 2015, 567, 12-21.	1.0	228

#	Article	IF	Citations
534	Predisposing roles of paraoxonase-1 genetic variants in Korean ischemic stroke patients. Genes and Genomics, 2015, 37, 579-586.	0.5	3
535	Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome. Redox Report, 2015, 20, 42-48.	1.4	12
536	Measurement of activity and concentration of paraoxonase 1 (PONâ€1) in seminal plasma and identification of PONâ€2 in the sperm of boar ejaculates. Molecular Reproduction and Development, 2015, 82, 58-65.	1.0	20
537	Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy. Cardiovascular Drugs and Therapy, 2015, 29, 41-50.	1.3	16
538	The role of metabolic syndrome in heart failure. European Heart Journal, 2015, 36, 2630-2634.	1.0	96
539	Association Between Paraoxonase Gene Polymorphisms and Intracerebral Hemorrhage in a Korean Population. Journal of Molecular Neuroscience, 2015, 57, 410-416.	1.1	7
540	PON1 polymorphisms are predictors of ability to attain HDL-C goals in statin-treated patients. Clinical Biochemistry, 2015, 48, 1039-1044.	0.8	8
541	Q192R Polymorphism of Paraoxonase 1 Gene Associated with Insulin Resistance in Mexican Children. Archives of Medical Research, 2015, 46, 78-83.	1.5	16
542	The effect of lifestyle change and metformin therapy on serum arylesterase and paraoxonase activity in obese children. Journal of Pediatric Endocrinology and Metabolism, 2015, 28, 551-6.	0.4	6
543	PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity. Journal of Lipid Research, 2015, 56, 1351-1362.	2.0	15
544	Association between butyrylcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: Correlation with systemic inflammatory markers and oxidative stress, preliminary report. Clinical Biochemistry, 2015, 48, 63-69.	0.8	35
545	Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol. Korean Circulation Journal, 2016, 46, 309.	0.7	2
546	AÃ§ai (Euterpe oleraceaMart.) Upregulates Paraoxonase 1 Gene Expression and Activity with Concomitant Reduction of Hepatic Steatosis in High-Fat Diet-Fed Rats. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	1.9	25
547	Concentration of Smaller Highâ€Density Lipoprotein Particle (HDLâ€P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA). Journal of the American Heart Association, 2016, 5, .	1.6	34
548	Increased presence of oxidized low-density lipoprotein in the left ventricular blood of subjects with cardiovascular disease. Physiological Reports, 2016, 4, e12726.	0.7	8
549	Ethnic differences in serum lipids and lipoproteins in overweight/obese African-American and white American women with pre-diabetes: significance of NMR-derived lipoprotein particle concentrations and sizes. BMJ Open Diabetes Research and Care, 2016, 4, e000246.	1.2	12
550	The effect of HDL-bound and free PON1 on copper-induced LDL oxidation. Chemico-Biological Interactions, 2016, 257, 141-146.	1.7	10
551	Assessment of human paraoxonase activity by electrochemistry: a simple and novel approach. Analytical Methods, 2016, 8, 8141-8146.	1.3	2

#	Article	IF	Citations
552	Effect of Continuous and Intermittent Exercises on Oxidised HDL and LDL Lipids in Runners. International Journal of Sports Medicine, 2016, 37, 1103-1109.	0.8	10
553	Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA. Journal of Lipid Research, 2016, 57, 2138-2149.	2.0	21
554	Racial Differences in DNA-Methylation of CpG Sites Within Preterm-Promoting Genes and Gene Variants. Maternal and Child Health Journal, 2016, 20, 1680-1687.	0.7	17
555	Nevirapine modulation of paraoxonase-1 in the liver: An in vitro three-model approach. European Journal of Pharmaceutical Sciences, 2016, 82, 147-153.	1.9	7
556	Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. Molecular and Cellular Proteomics, 2016, 15, 1083-1093.	2.5	23
557	A study of paraoxonase1 (PON1) activities, HDL cholesterol and its association with vascular complication in type 2 diabetes mellitus. International Journal of Diabetes in Developing Countries, 2016, 36, 457-462.	0.3	3
558	Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. Atherosclerosis, 2016, 245, 143-154.	0.4	73
559	Intake of up to 3 Eggs per Day Is Associated with Changes in HDL Function and Increased Plasma Antioxidants in Healthy, Young Adults. Journal of Nutrition, 2017, 147, 323-329.	1.3	48
560	Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circulation Research, 2017, 120, 713-735.	2.0	962
561	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 2017, 23, 1-87.	1.1	766
562	Active Site Hydrophobicity and the Convergent Evolution of Paraoxonase Activity in Structurally Divergent Enzymes: The Case of Serum Paraoxonase 1. Journal of the American Chemical Society, 2017, 139, 1155-1167.	6.6	63
563	Antiepileptic drugs: Impacts on human serum paraoxonaseâ€1. Journal of Biochemical and Molecular Toxicology, 2017, 31, e21889.	1.4	55
564	The Changing Face of HDL and the Best Way to Measure It. Clinical Chemistry, 2017, 63, 196-210.	1.5	86
565	Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clinical, 2017, 8, 66-77.	4.1	161
566	Organophosphate pesticides and PON1 L55M in Parkinson's disease progression. Environment International, 2017, 107, 75-81.	4.8	43
567	Antioxidant effect of Arabian coffee (<i>Coffea arabica</i> L) blended with cloves or cardamom in high-fat diet-fed C57BL/6J mice. Tropical Journal of Pharmaceutical Research, 2017, 16, 1545.	0.2	3
568	Joint Effects of PON1 Polymorphisms and Vegetable Intake on Ischemic Stroke: A Family-Based Case Control Study. International Journal of Molecular Sciences, 2017, 18, 2652.	1.8	12
569	Hydroxytyrosol in the Prevention of the Metabolic Syndrome and Related Disorders. Nutrients, 2017, 9, 306.	1.7	93

#	Article	IF	Citations
570	Disparities in Cardiovascular Disease and Type 2 Diabetes Risk Factors in Blacks and Whites: Dissecting Racial Paradox of Metabolic Syndrome. Frontiers in Endocrinology, 2017, 8, 204.	1.5	37
571	Sera from Visceral Leishmaniasis Patients Display Oxidative Activity and Affect the TNF-Î±Production by MacrophagesIn Vitro. BioMed Research International, 2017, 2017, 1-6.	0.9	5
572	Paraoxonase 1 and Its Clinical Relevance. , 2017, , 187-208.		1
573	The role of cholesterol-enriched diet and paraoxonase 1 inhibition in atherosclerosis progression. Journal of Cardiovascular and Thoracic Research, 2017, 9, 133-139.	0.3	7
574	Carotenoids Regulate Endothelial Functions and Reduce the Risk of Cardiovascular Disease. , 0, , .		6
575	Degenerated HDL and Its Clinical Implications. , 2017, , 37-63.		0
576	Functional SNP in the 3â€™UTR of PON1 is Associated with the Risk of Calcific Aortic Valve Stenosis via MiR-616. Cellular Physiology and Biochemistry, 2018, 45, 1390-1398.	1.1	7
577	Relationship Between Paraoxonase-1 and Butyrylcholinesterase Activities and Nutritional Status in Mexican Children. Metabolic Syndrome and Related Disorders, 2018, 16, 90-96.	0.5	4
578	Serum paraoxonaseâ€1 activity is inversely related to free thyroxine in euthyroid subjects: The <scp>PREVEND</scp> Cohort Study. European Journal of Clinical Investigation, 2018, 48, e12860.	1.7	2
579	Endothelial Protective Effects of Dietary Phytochemicals: Focus on Polyphenols and Carotenoids. Studies in Natural Products Chemistry, 2018, , 323-350.	0.8	3
580	Influences of PON1 on airway inflammation and remodeling in bronchial asthma. Journal of Cellular Biochemistry, 2018, 119, 793-805.	1.2	13
581	Activity of the antioxidant enzyme paraoxonase in Argentinean children living at high altitude. Redox Report, 2018, 23, 35-40.	1.4	4
582	Terminalia pallida fruit ethanolic extract ameliorates lipids, lipoproteins, lipid metabolism marker enzymes and paraoxonase in isoproterenol-induced myocardial infarcted rats. Saudi Journal of Biological Sciences, 2018, 25, 431-436.	1.8	7
583	ROLE OF APELIN/MONOCYTE CHEMOATTRACTANT PROTEIN-1, INFLAMMATORY, APOPTOTIC MARKERS IN THE REGULATION OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 138.	0.3	1
584	Effects of selenium supplementation on paraoxonase-1 and myeloperoxidase activity in subjects with cardiovascular disease: the Selenegene study, aÂdouble-blind randomized controlled trial. Archives of Medical Sciences Atherosclerotic Diseases, 2018, 3, 112-118.	0.5	4
585	The pleiotropic vasoprotective functions of high density lipoproteins (HDL). Journal of Biomedical Research, 2018, 32, .	0.7	23
586	Oxidized Low-Density Lipoprotein to High-Density Lipoprotein Ratio Predicts Recurrent Stroke in Minor Stroke or Transient Ischemic Attack. Stroke, 2018, 49, 2637-2642.	1.0	9
587	Cross-sectional correlates of paraoxonase 1 and soluble intercellular adhesion molecule-1 in metabolic syndrome patients with and without diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 303-310.	1.4	1

#	Article	IF	Citations
588	High-density lipoprotein carbamylation and dysfunction in vascular disease. Frontiers in Bioscience - Landmark, 2018, 23, 2227-2234.	3.0	10
589	Decreased serum PON1 arylesterase activity in familial hypercholesterolemia patients with a mutated LDLR gene. Genetics and Molecular Biology, 2018, 41, 570-577.	0.6	11
590	Pharmacological Intervention to Modulate HDL: What Do We Target?. Frontiers in Pharmacology, 2017, 8, 989.	1.6	47
591	Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vascular Health and Risk Management, 2018, Volume 14, 137-143.	1.0	101
592	Effect of ubiquinol supplementation on biochemical and oxidative stress indexes after intense exercise in young athletes. Redox Report, 2018, 23, 136-145.	1.4	41
593	Biomarkers in Metabolic Syndrome. , 0, , .		3
594	Paraoxonases Activities and Polymorphisms in Elderly and Old-Age Diseases: An Overview. Antioxidants, 2019, 8, 118.	2.2	39
595	Elevated serum OxLDL is associated with progression of type 2 Diabetes Mellitus to diabetic retinopathy. Experimental Eye Research, 2019, 186, 107668.	1.2	9
596	PON1 arylesterase activity, HDL functionality and their correlation in malnourished children. Journal of Pediatric Endocrinology and Metabolism, 2019, 32, 321-326.	0.4	4
597	Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?. Current Neuropharmacology, 2019, 17, 1004-1020.	1.4	45
598	Interaction between MTHFR 677C>T, PON1 192Q>R and PON1 55L>M polymorphisms and its effect on non-recurrent spontaneous abortion in Mexican women. Gene, 2019, 689, 69-75.	1.0	3
599	Effects of Paraoxonase-1 variants on course of severity and mortality of Crimean-Congo hemorrhagic fever. Gene, 2019, 687, 188-192.	1.0	2
600	Association of antioxidant status and inflammatory markers with metabolic syndrome in Thais. Journal of Health, Population and Nutrition, 2019, 38, 1.	0.7	37
601	Îhe Antioxidant Function of HDL in Atherosclerosis. Angiology, 2020, 71, 112-121.	0.8	28
602	Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes. International Urology and Nephrology, 2020, 52, 1725-1732.	0.6	3
603	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews, 2020, 159, 4-33.	6.6	113
604	Highâ€density lipoproteinâ€related cholesterol metabolism in Alzheimerâ€™s disease. Journal of Neurochemistry, 2021, 159, 343-377.	2.1	8
605	Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory?. Arthritis Research and Therapy, 2020, 22, 213.	1.6	9

#	Article	IF	Citations
606	High-Density Lipoprotein-Targeted Therapies for Heart Failure. Biomedicines, 2020, 8, 620.	1.4	9
607	Do PON1â€“Q192R and PON1â€“L55M polymorphisms modify the effects of hypoxic training on paraoxonase and arylesterase activity?. Journal of Sport and Health Science, 2023, 12, 266-274.	3.3	4
608	Evaluation of Daily Laurus nobilis Tea Consumption on Lipid Profile Biomarkers in Healthy Volunteers. Journal of the American College of Nutrition, 2020, 39, 733-738.	1.1	8
609	Paraoxonase-1 Enzyme Activity and Oxidative Status in Pulmonary Hypertension Original Article. Bangladesh Journal of Medical Science, 2020, 19, 652-658.	0.1	0
610	Association between rs662 (Aâ€‰>â€‰G) and rs854560 (Aâ€‰>â€‰T) polymorphisms in PON1 gene and the susceptibility for psoriasis in mestizo population of Western Mexico. Molecular Biology Reports, 2021, 48, 183-194.	1.0	6
611	Evaluation of the relationship between serum paraoxonase-1 activity and superovulation response/embryo yield in Holstein cows. Journal of Veterinary Medical Science, 2021, 83, 535-541.	0.3	1
612	Paraoxonaseâ€1 (PON1) Status Analysis Using Nonâ€Organophosphate Substrates. Current Protocols, 2021, 1, e25.	1.3	7
613	Glutamine-Arginine 192 Polymorphism of Paraoxonase 1 Gene in Coronary Artery Disease Patients Compared to Healthy Controls in a Study from Kerala. Journal of Evidence Based Medicine and Healthcare, 2021, 8, 136-140.	0.0	0
614	Astaxanthin for improved muscle function and enhanced physical performance. , 2021, , 447-467.		1
615	Menstruation distress is strongly associated with hormone-immune-metabolic biomarkers. Journal of Psychosomatic Research, 2021, 142, 110355.	1.2	12
616	PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study. PLoS ONE, 2021, 16, e0254067.	1.1	1
617	Paraoxonase 1 gene variants concerning cardiovascular mortality in conventional cigarette smokers and non-smokers treated with hemodialysis. Scientific Reports, 2021, 11, 19467.	1.6	2
618	Oxidative Stress in the Metabolic Syndrome. , 2009, , 33-63.		2
619	The Role of Paraoxonase in Lipid Metabolism. , 2002, , 79-92.		5
620	LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: Role of prooxidants vs. antioxidants. , 1998, , 149-159.		31
621	The Human Serum Paraoxonase Polymorphism and Atherosclerosis. , 1994, , 65-73.		9
622	Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins. Diabetologia, 1996, 39, 667-676.	2.9	6
623	Paraoxonase 1 gene polymorphisms and enzyme activities in coronary artery disease and its relationship to serum lipids and glycemia. Archivos De Cardiologia De Mexico, 2016, 86, 350-357.	0.1	18

#	Article	IF	Citations
624	Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonase1 activity. Journal of Lipid Research, 2002, 43, 713-720.	2.0	56
625	Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. Journal of Lipid Research, 2002, 43, 477-485.	2.0	73
626	A new enzyme-linked immunosorbent assay with two monoclonal antibodies to specific epitopes measures human lecithin-cholesterol acyltransferase. Journal of Lipid Research, 2002, 43, 325-334.	2.0	26
627	Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. Journal of Lipid Research, 2001, 42, 528-535.	2.0	83
628	Baculovirus-mediated expression and purification of human serum paraoxonase 1A. Journal of Lipid Research, 2001, 42, 951-958.	2.0	37
629	Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Qâ†'R genetic polymorphism. Journal of Lipid Research, 1999, 40, 133-139.	2.0	110
630	A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. Journal of Lipid Research, 2000, 41, 1358-1363.	2.0	51
631	Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. Journal of Lipid Research, 1999, 40, 1276-1283.	2.0	40
632	HDL antioxidant effects as assessed using a nonexchangeable probe to monitor particle-specific peroxidative stress in LDL-HDL mixtures.. Journal of Lipid Research, 1995, 36, 2580-2589.	2.0	25
633	Paraoxonase and coronary heart disease. Current Opinion in Lipidology, 1998, 9, 319-324.	1.2	177
634	Paraoxonase-1 gene Leu-Met55 and Gln-Arg192 polymorphisms are not associated with carotid artery atherosclerosis in a population-based cohort. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 511-512.	3.1	6
635	Lowering of HDL _{2b} by Probucol Partly Explains the Failure of the Drug to Affect Femoral Atherosclerosis in Subjects With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1049-1056.	1.1	72
636	Paraoxonase Genotypes, Lipoprotein Lipase Activity, and HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1243-1249.	1.1	73
637	Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model.. Journal of Clinical Investigation, 1996, 97, 1630-1639.	3.9	227
638	Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.. Journal of Clinical Investigation, 1997, 99, 62-66.	3.9	433
639	Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.. Journal of Clinical Investigation, 1997, 99, 2005-2019.	3.9	271
640	Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.. Journal of Clinical Investigation, 1997, 100, 464-474.	3.9	160
641	Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.. Journal of Clinical Investigation, 1998, 101, 1581-1590.	3.9	1,009

#	Article	IF	Citations
642	Paraoxonase-1 (PON1) rs662 Polymorphism and Its Association with Serum Lipid Levels and Longevity in the Bama Zhuang Population. Medical Science Monitor, 2016, 22, 5154-5162.	0.5	7
643	Maternal and Fetal Genetic Associations of PTGER3 and PON1 with Preterm Birth. PLoS ONE, 2010, 5, e9040.	1.1	27
644	Paraoxonase 2 Protein Is Spatially Expressed in the Human Placenta and Selectively Reduced in Labour. PLoS ONE, 2014, 9, e96754.	1.1	3
645	Decrease of serum paraoxonase activity in chronic renal failure.. Journal of the American Society of Nephrology: JASN, 1998, 9, 2082-2088.	3.0	153
646	Effects of Silymarin Supplementation on Leptin, Adiponectin and Paraoxanase Levels and Body Composition During Exercise: A Randomized Double-Blind Placebo Controlled Clinical Trial. Jundishapur Journal of Natural Pharmaceutical Products, 2016, 11, .	0.3	6
647	Species- and substrate-specific stimulation of human plasma paraoxonase 1 (PON1) activity by high chloride concentration.. Acta Biochimica Polonica, 2002, 49, 927-936.	0.3	23
648	Inhibition Effects of Phenolic Compounds on Human Serum Paraoxonase-1 Enzyme. Journal of the Institute of Science and Technology, 0, , 1013-1022.	0.3	29
649	Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment. Current Pharmaceutical Design, 2019, 25, 969-986.	0.9	24
650	Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?. Current Pharmaceutical Design, 2019, 25, 3128-3146.	0.9	10
651	A High Throughput Serum Paraoxonase Assay for Discovery of Small Molecule Modulators of PON1 Activity. Current Chemical Genomics, 2008, 2, 51-61.	2.0	8
652	Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clinical and Investigative Medicine, 2011, 34, 163.	0.3	106
653	Whole-Body Cryostimulation Improves Inflammatory Endothelium Parameters and Decreases Oxidative Stress in Healthy Subjects. Antioxidants, 2020, 9, 1308.	2.2	17
654	Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors. World Journal of Gastroenterology, 2015, 21, 2875.	1.4	8
655	Raw Allium sativum as Performance Enhancer and Hypocholesterolemic Agent in Laying Hens. Asian Journal of Animal and Veterinary Advances, 2018, 13, 210-217.	0.3	2
656	Trend of Prevalence of Low HDL-Cholesterol and Related Factors in Korean Men: Using 3 Korean National Health and Nutrition Examination Survey Data (1998-2005). Korean Journal of Family Medicine, 2010, 31, 755.	0.4	2
657	A single session of aerobic exercise influences paraoxonase 1 activity and concentration (Una sola) Tj ETQq1 1 0.784314 rgBT /Overlo 222-225.	0.3	3
658	Distribution of Pon L/M55 and Q/R192 Genotypes in Turkish Patients with Angiographically-Defined Coronary Artery Disease: Effects on Serum Lipids. Turkiye Klinikleri Journal of Medical Sciences, 2013, 33, 769-776.	0.1	1
659	Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World Journal of Virology, 2015, 4, 56.	1.3	97

#	Article	IF	Citations
660	HDL2 Can Inhibit Further Oxidative Modification of Partially Oxidized LDL. Journal of Atherosclerosis and Thrombosis, 2010, 17, 229-234.	0.9	3
661	Effect of vitamin e and selenium supplement on paraoxonase-1 activity, oxidized low density lipoprotein and antioxidant defense in diabetic rats. BioImpacts, 2011, 1, 121-8.	0.7	25
662	Differentially expressed serum proteins associated with calcium regulation and hypocalcemia in dairy cows. Asian-Australasian Journal of Animal Sciences, 2017, 30, 893-901.	2.4	1
663	Gender-dependent difference in serum paraoxonase 1 levels of Hanwoo, Korean native cattle, and a positive association with meat quality. Asian-Australasian Journal of Animal Sciences, 2019, 32, 437-441.	2.4	2
665	Lipoproteins and Oxidation: Clinical Aspects of Lipoprotein Metabolism and Oxidation. Developments in Cardiovascular Medicine, 2000, , 1-18.	0.1	0
666	Antioxidant Defenses in the Vascular Wall. Developments in Cardiovascular Medicine, 2000, , 27-47.	0.1	0
667	Paraoxonase (PON1) and polymorphisms of PON1 gene. The Journal of Japan Atherosclerosis Society, 2000, 27, 105-110.	0.0	0
668	Environmental Tobacco Smoke. , 2000, , 195-205.		0
669	Oxidative Stress in Cardiovascular Disease. Oxidative Stress and Disease, 2003, , .	0.3	5
670	Molekulare Grundlagen altersspezifischer Erkrankungen des Herz-Kreislauf-Systems und der Arteriosklerose. , 2004, , 371-401.		2
671	Lipid and Lipoprotein Metabolism. , 2005, , 47-60.		2
673	Paraoxonase 1 Status, Environmental Exposures, and Oxidative Stress in Autism Spectrum Disorders. , 2009, , 91-112.		0
675	Atherothrombosis in South Asians: Implications of Atherosclerotic and Inflammatory Markers~!2009-11-05~!2009-12-04~!2010-02-22~!. Open Cardiovascular Medicine Journal, 2010, 4, 45-50.	0.6	1
676	Atherothrombosis in South Asians: Implications of Atherosclerotic and Inflammatory Markers. Open Cardiovascular Medicine Journal, 2010, 4, 45-50.	0.6	4
678	Changes in the Serum Level of High Density Lipoprotein-cholesterol after Smoking Cessation among Adult Men. Korean Journal of Family Medicine, 2012, 33, 305.	0.4	2
679	Paraoxonase 1 gene (Gln¹⁹²-Arg) polymorphism and the risk of coronary artery disease in type 2 diabetes mellitus. World Journal of Cardiovascular Diseases, 2012, 02, 29-37.	0.0	0
680	Severe Thromboembolism and Systemic Lupus Erythematosus Developing after Ovarian Hyperstimulation in a Persistent Carrier of Antiphospholipid Antibodies. Journal of Hematology & Thromboembolic Diseases, 2014, 02, .	0.1	0
681	Atherosclerosis in Primary Antiphospholipid Syndrome: Summary of Clinical and Pathogenic Evidence. Journal of Clinical & Experimental Cardiology, 2014, 05, .	0.0	1

#	Article	IF	Citations
682	Paraoxonase 192Gln-Arg polymorphism in the patients with coronary artery disease and cerebral infarction. The Journal of Japan Atherosclerosis Society, 1998, 26, 111-116.	0.0	0
683	Title is missing!. Journal of Lipid Nutrition, 1999, 8, 11-24.	0.1	0
684	The effects of n-3 fatty acids intake on PON1 activity and fatty acid status in type 2 diabetic patients â€“ A pilot study. El Mednifico Journal, 2014, 2, 328.	0.1	0
685	The Role of Fetuin-A in Disease Processes Prevalent in Postmenopausal Women (El papel de la fetuina A) Tj ETQq1 1 0.784314 rgBT /Ov	0.3	0
686	Mannan oligosakkarit (MOS) Ä°laveli Yemlerle Beslenen Oreochromis niloticusâ€™un KaraciÄŸer Paraoksonaz Enzim Aktivitesi ve Malondialdehit DÃ¼zeyinin AraÅŸtÄ±rÄ±lmasÄ±. Turkish Journal of Agriculture: Food Science and Technology, 2015, 3, 639.	0.1	0
687	Lipoprotein-Associated Oxidative Stress. , 2016, , 67-89.		1
689	ASSESSMENT OF PARAOXONASE-1 ACTIVITY IN DIABETES MELLITUS. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 6420-6424.	0.1	0
690	SERUM PARAOXONASE ACTIVITY IN RENAL TRANSPLANT RECIPIENTS. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 5703-5706.	0.0	0
691	Plasma paraoxonase1 activity in rats treated with monocrotophos: a study of the effect of duration of exposure. Interdisciplinary Toxicology, 2019, 12, 129-135.	1.0	0
693	Helikobakter Pilori Eradikasyonun Serum Paraoksonaz Enzim Aktivitesine Etkisi. Ankara EÄŸitim Ve AraÅŸtÄ±rma Hastanesi TÄ±p Dergisi, 2020, 53, 82-85.	0.1	0
694	Risk Factors. , 2005, , 475-516.		0
695	Isolation and complete covalent structure of liver microsomal paraoxonase. Biochemical Journal, 1999, 338 (Pt 2), 265-72.	1.7	5
696	Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis. American Journal of Cardiovascular Disease, 2012, 2, 123-32.	0.5	2
697	Physical activity, nutrition, and dyslipidemia in middle-aged women. Iranian Journal of Public Health, 2011, 40, 89-98.	0.3	18
698	Protective effect of paraoxonase 1 gene variant L55M in retinal vein occlusion. Molecular Vision, 2013, 19, 486-xxx.	1.1	2
699	Serum Paraoxonase Levels are Correlated with Impaired Aortic Functions in Patients with Chronic Kidney Disease. Acta Cardiologica Sinica, 2016, 32, 75-80.	0.1	3
700	Paraoxonase activity in metabolic syndrome in children and adolescents. Caspian Journal of Internal Medicine, 2018, 9, 116-120.	0.1	4
701	Role of Oxidative Stress in Heart Failure: Insights from Gene Transfer Studies. Biomedicines, 2021, 9, 1645.	1.4	12

#	Article	IF	Citations
702	Effect of subacute malathion application on oxidative stress biomarkers. Journal of Advances in VetBio Science and Techniques, 2021, 6, 193-201.	0.1	3
703	Association Between PON1 (L55M and Q192R) Genetic Polymorphism and Recurrent Pregnancy Loss in North Indian Women Exposed to Pesticides. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 805-810.	0.3	1
704	HDL Is Not Dead Yet. Biomedicines, 2022, 10, 128.	1.4	8
705	LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Molecular and Cellular Biochemistry, 1998, 188, 149-59.	1.4	22
706	Impact of Seminal Plasma Antioxidants on Donkey Sperm Cryotolerance. Antioxidants, 2022, 11, 417.	2.2	7
707	Paraoxonase and arylesterase activity of serum PON-1 enzyme in psoriatic patients: a systematic review and meta-analysis. Clinical and Experimental Medicine, 2023, 23, 301-311.	1.9	5
708	The Relationship between Cancer and Paraoxonase 1. Antioxidants, 2022, 11, 697.	2.2	13
709	HDL Composition, Heart Failure, and Its Comorbidities. Frontiers in Cardiovascular Medicine, 2022, 9, 846990.	1.1	12
710	Role of Oxidative Stress in Diabetic Cardiomyopathy. Antioxidants, 2022, 11, 784.	2.2	51
711	Sensitive Assay for the Lactonase Activity of Serum Paraoxonase 1 (PON1) by Harnessing the Fluorescence Turn-On Characteristics of Bioorthogonally Synthesized and Geometrically Controlled Chemical Probes. Molecules, 2022, 27, 2435.	1.7	1
715	High-Density Lipoprotein and Atheroprotection. , 0, , 95-107.		0
719	Could the PON1 phenotype play a key role in insulin resistance?. International Journal of Diabetes in Developing Countries, 0, , .	0.3	0
720	MicroRNA 155, Factor XIII and Type 2 Diabetes Mellitus and Coronary Heart Disease. Current Diabetes Reviews, 2022, 19, .	0.6	1
721	Oxidative modification of HDL by lipid aldehydes impacts HDL function. Archives of Biochemistry and Biophysics, 2022, 730, 109397.	1.4	5
722	Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?. Lipids in Health and Disease, 2022, 21, .	1.2	8
723	Cardioprotective Role for Paraoxonase-1 in Chronic Kidney Disease. Biomedicines, 2022, 10, 2301.	1.4	3
724	Alterations of HDLâ€™s to piHDLâ€™s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. Pharmaceuticals, 2022, 15, 1278.	1.7	9
725	Paraoxonase Activity an Independent Contributor in SARS-CoV-2 Infection. Turkish Journal of Internal Medicine, 0, , .	0.3	0

#	Article	IF	Citations
726	HDL Isolated by Immunoaffinity, Ultracentrifugation, or Precipitation is Compositionally and Functionally Distinct. Journal of Lipid Research, 2022, 63, 100307.	2.0	7
727	A systematic review and meta-analysis of paraoxonase-1 activity in asthma. Clinical and Experimental Medicine, 2023, 23, 1067-1074.	1.9	3
728	Effect of dialyzer reuse on the activity of paraoxonase 1 in patients on hemodialysis. Indian Journal of Nephrology, 2022, 32, 606.	0.2	1
729	Microalgae as a Nutraceutical Tool to Antagonize the Impairment of Redox Status Induced by SNPs: Implications on Insulin Resistance. Biology, 2023, 12, 449.	1.3	1
730	Paraoxonase 1 and atherosclerosis. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	8
731	Vutiglabridin Modulates Paraoxonase 1 and Ameliorates Diet-Induced Obesity in Hyperlipidemic Mice. Biomolecules, 2023, 13, 687.	1.8	1